1 2 3 4 5 6 7 8 9 10 11 12 13 14		e] ES DISTRICT COURT RICT OF CALIFORNIA
15	LINDA HEARNE, individually,	Case No. 8:20-CV-00823
 16 17 18 19 20 21 22 23 24 25 26 27 28 	Plaintiff, v. ALLERGAN, INC. f/k/a INAMED CORPORATION f/k/a MCGHAN MEDICAL CORPORATION; ALLERGAN HOLDCO U.S., INC.; ALLERGAN HOLDINGS, INC.; ALLERGAN SALES, LLC; ALLERGAN USA, INC.; ALLERGAN PLC; and DOES 1 through 100, inclusive, Defendants	 COMPLAINT AND DEMAND FOR JURY TRIAL 1. Strict Product Liability-Failure to Warn 2. Strict Product Liability-Manufacturing Defect 3. Negligence 4. Intentional Misrepresentation/ Concealment 5. Negligent Misrepresentation/ Concealment
		-1-
	COMPLAINT AND	DEMAND FOR JURY TRIAL

Plaintiff LINDA HEARNE ("Plaintiff") brings this action against 1 Defendants ALLERGAN, INC., ALLERGAN HOLDCO U.S., INC., 2 ALLERGAN HOLDINGS, INC., ALLERGAN SALES, LLC, ALLERGAN USA, 3 INC., ALLERGAN PLC (all corporations headquartered in California with their 4 principal place of business and key executives located in California; collectively 5 referred to as "Defendants" or "ALLERGAN"), and DOES 1-100 seeking 6 damages arising out of ALLERGAN's negligence, deceit, concealment, and 7 misrepresentations concerning the deadly and defective condition of its BIOCELL 8 **Textured Breast Implants.** 9

INTRODUCTION

1. ALLERGAN is a global company that has long pushed a portfolio of 12 consumer products in the medical aesthetics, eye care, central nervous system, and 13 gastroenterology fields. Among its portfolio of products is a specific type of breast 14 implant and tissue expander for cosmetic and reconstructive surgery, referred to 15 broadly herein as the BIOCELL Textured Breast Implant suite of products. 16 ALLERGAN developed, sought regulatory approval for, marketed, advertised, 17 manufactured, distributed, and sold those BIOCELL Textured Breast Implants 18 through its primary office in the United States, located in Irvine, California. 19

Across multiple generations of the product, ALLERGAN has sold 2. 20 hundreds of thousands of textured breast implants and developed and marketed 21 22 dozens of additional styles incorporating their BIOCELL technology. Those products have been sold worldwide, and have been implanted into tens, if not 23 hundreds, of thousands of California and United States consumers. This was highly 24 profitable for ALLERGAN, which received tens, if not hundreds, of *millions* of 25 dollars' worth of revenue through its sale and distribution of the BIOCELL 26 Textured Breast Implants to consumers across the world. 27

28

10

3. ALLERGAN has longed claimed that these products are safe for 1 2 consumer use, and based on those promises they have been widely used by women for both reconstructive surgery—particularly after a breast cancer diagnosis, genetic 3 testing, or other concern-as well as for cosmetic uses. 4

5

But those products pose a significant risk—a risk that was *long* hidden 4. and buried by ALLERGAN in advertisements, flyers, reports, and other 6 communications to both the marketplace and the FDA. ALLERGAN'S BIOCELL 7 Textured Breast Implants have a surface roughness significantly higher than the 8 industry standard and are capable of embedding silicone surface particles in the 9 fibrous scar tissue that naturally forms around the implant, known as the "capsule." 10

5. In part because of that flaw, the medical and scientific consensus has 11 determined that the extreme texturing of the implants, when combined with a 12 bacterial accumulation or a genetic predisposition, form a perfect storm for the 13 development of Breast Implant Associated–Anaplastic Large Cell Lymphoma 14 (BIA-ALCL).¹ BIA-ALCL is an uncommon but emerging subtype of non-15 Hodgkin's lymphoma—a cancer that originates from lymphatic cells, which are part 16 of the immune system. BIA-ALCL is thus a cancer of the immune system, and not 17 a type of breast cancer. 18

Because of the processes used in their manufacture, ALLERGAN's 19 6. BIOCELL Textured Breast Implants increase the likelihood of a woman developing 20 BIA-ALCL dramatically from other textured breast implants on the market, with 21 22 one study finding that the nexus jumps approximately 10 times from other products on the US marketplace. 23

- 24
- 25
- 26
- 27

28

¹Allergan's Vice President of Clinical Development, Stephanie Manson Brown, acknowledged—while still downplaying—that "[h]igher implant surface area may be a risk factor" because "[s]urface area contributes to bacterial accumulation" in her presentation at the FDA Medical Devices Advisory Committee General and Plastic Surgery Devices Panel on March 25, 2019.

7. Despite the grave risks posed by its BIOCELL Textured Breast 1 2 Implants, and the ready possibility of a safer product, ALLERGAN has for decades orchestrated a disinformation campaign aimed at discrediting and concealing the 3 clearly established link between the occurrence of BIA-ALCL and the presence of 4 an ALLERGAN BIOCELL Textured Breast Implant. This was done in the interest 5 of placing ALLERGAN's pecuniary interest and profits over public safety, so that 6 7 ALLERGAN could continue to sell and distribute a dangerous product into the marketplace at great financial gain to the company. 8

8. For example, Plaintiff is informed and believes and thereon alleges
that between 2007 and 2010—following premarket approval for its first generation
of silicone-filled breast implants—ALLERGAN received worldwide 22 complaints
of BIA-ALCL in women implanted with the silicone brand of the BIOCELL
Textured Breast Implants. Despite the public health crisis implicated by such
statistics, ALLERGAN unlawfully failed to report these events of BIA-ALCL to
the FDA *at all*.

9. Thereafter, as events of BIA-ALCL continued to surface, 16 ALLERGAN doubled-down on its unlawful concealment efforts by abusing its 17 unique adverse health event summary reporting privilege for its breast implants, 18 known as Alternative Summary Reporting. *This privilege was available only for* 19 specific adverse event types associated with breast implants where compliance 20 with some of the reporting requirements was not necessary to protect the public 21 22 *health because such events were known and well-documented.* Despite its ineligibility for summary reporting, from at least 2009 until 2019 when the 23 Alternative Summary Reporting was discontinued due to misuse, ALLERGAN 24 buried complaints of BIA-ALCL, and symptoms associated therewith, transmitted 25 to the company from health care professionals, user facilities, and patients in the 26 unscrutinized summary reporting spreadsheets which only recently became publicly 27 available. 28

-4-

10. Because ALLERGAN failed to perform its duties under federal law to 1 2 warn the FDA about BIA-ALCL, and because ALLERGAN failed to comply with 3 its reporting duties under federal law with respect to BIA-ALCL, Plaintiff's claims set forth below are not subject to preemption. 4

5

11. Plaintiff is informed and believes and thereon alleges that at all times ALLERGAN allowed their BIOCELL Textured Breast Implants to remain in the 6 market knowing they suffered from a serious safety defect/risk and failed to 7 disclose, concealed, and misrepresented the important safety risks associated with 8 textured breast implants in representations made to Plaintiff and the FDA, 9 specifically the clear links between ALLERGAN's BIOCELL Textured Breast 10 Implants and BIA-ALCL. ALLERGAN misrepresented the scope of the risk, failed 11 to publicly report the cases of BIA-ALCL that *had* been caused by its products as it 12 was obligated to do under federal law and regulations, and failed to remedy the 13 danger to consumers around the world and across the country. 14

12. Had Plaintiff known the truth about ALLERGAN's BIOCELL 15 Textured Breast Implants, she would not have had them implanted into her body. 16 Instead, she would have, among other things, forwent implantation, or chosen 17 smooth or microtextured implants, thereby avoiding the heightened risk of 18 developing BIA-ALCL. 19

Finally, after decades of misrepresenting and hiding the scope of the 20 13. 21 problem—and the danger posed to women with these implanted products—the 22 cancerous propensities of ALLERGAN's product finally started coming to light. On December 18, 2018, ALLERGAN was banned from selling its BIOCELL 23 textured implants in the European Union based on health and safety concerns. Five 24 months later, Health Canada suspended ALLERGAN's license to sell BIOCELL 25 Textured Breast Implants in Canada following a safety review that brought to light 26 the increased risk of BIA-ALCL amongst those implanted with BIOCELL Textured 27 28

Breast Implants sold by the Defendants. Yet ALLERGAN continued to sell its 1 textured implants in the United States. 2

14. On July 24, 2019, the FDA announced the world-wide recall of ALLERGAN's BIOCELL Textured Breast Implants in order to "protect individuals 4 from the increased risk of BIA-ALCL, associated with BIOCELL textured breast implants."² 6

3

5

15. Following that recall, and with knowledge of the danger *finally* being 7 provided to the public, numerous consumers across the country are left with fear, 8 concern, and worry that their ALLERGAN BIOCELL Textured Breast Implants 9 have now exposed them to the dangers of BIA-ALCL. As is only reasonable, 10 people, like Plaintiff LINDA HEARNE, want these dangerous products out of their 11 bodies—yet ALLERGAN has refused to assist in providing for the surgical, 12 medical, hospital, facility, and many other expenses that will be incurred by 13 thousands upon thousands of women across the country, not to mention the stress, 14 fear, anxiety, and worry caused by the company's dangerous products. This action 15 16 is brought to remedy the dangerous, deceptive conduct of ALLERGAN resulting in 17 the implantation of these dangerous, defective products in Plaintiff LINDA HEARNE. 18

19 20

21

22

23

24

PARTIES

Plaintiff A.

16. Plaintiff LINDA HEARNE, is a resident of the state of Louisiana, Calcasieu Parish, and city of Lake Charles. On January 22, 1993, LINDA

 2 The FDA's analysis was attributed to a new worldwide reported total of 573 25 unique BIA-ALCL cases including 33 patient deaths. Of the 573 cases of BIA-26 ALCL, 481 are reported to have Allergan breast implants at the time of diagnosis. 27 In addition, 12 of 13 deaths occurring in patients with BIA-ALCL where the manufacturer was known occurred in patients implanted with an Allergan breast 28 implant at the time of their BIA-ALCL diagnosis.

HEARNE was implanted with an ALLERGAN saline-filled BIOCELL Textured
 Breast Implant.

17. Thereafter, LINDA HEARNE did not receive any update or warning
from ALLERGAN any time before or after her surgery in January 1993 about the
clearly established link between ALLERGAN's BIOCELL Textured Breast
Implants and BIA-ALCL.

7

8

9

18. Following the worldwide recall and revelations about the dangers of ALLERGAN's products, LINDA HEARNE underwent an explanation surgery on January 3, 2020 for the removal of the BIOCELL Textured Breast Implant.

10 19. Plaintiff had to pay out-of-pocket for the removal of the dangerous
11 textured breast implant because ALLERGAN has *refused* to do so.³

20. Plaintiff has worried about the risks she faces, has also been subject to
out-of-pocket expenses in relation to seeking medical advice, evaluating the flawed
product implanted into her body, and seeking recommendations for future care and
treatment. Plaintiff also continue to suffer from mental stress, anxiety, worry,
humiliation, fear, concern and other personal and financial hardship due to the
continuous fear of BIA-ALCL and aftermath from the suffering of BIA-ALCL.

18 21. Plaintiff has had to take time away from work in order to seek medical
19 treatment, advice, and consultation, and due to the stress and anxiety related to her
20 flawed ALLEGAN implants.

21 22. Plaintiff would not have had BIOCELL Textured Breast Implants
22 implanted in her or would have had them explanted sooner had the Defendants
23 honestly, fully, and completely disclosed the risks.

- 24 25
- -0
- 26

³ On July 30, 2019, following the worldwide recall, Carrie Strom, Senior Vice
President, U.S. Medical Aesthetics, Allergan plc, announced to customer that
"Allergan will not provide surgical fee assistance to revision patients."

B. Defendants

1

2 23. ALLERGAN does not adhere to the formalities of corporate structure,
3 but rather employs an extremely fluid corporate hierarchy through a series of
4 largely employee-less holding companies whereby the various entities within the
5 corporate structure serve as alter-egos of each other.

6 24. Defendant ALLERGAN PLC (formerly known as Actavis plc) is the
7 principal entity for the ALLERGAN business and was incorporated in Ireland on
8 May 16, 2013.

9 25. Defendant ALLERGAN PLC ordinary shares are traded on the NYSE
10 under the ticker symbol "AGN."

26. Defendant ALLERGAN PLC represents itself to the public as a global 11 specialty pharmaceutical company engaged in the development, manufacturing, 12 marketing, and distribution of brand name pharmaceutical products, medical 13 aesthetics, biosimilar, and over-the-counter pharmaceutical products. Conversely, 14 when convenient, Defendant ALLERGAN PLC represents that it is simply a 15 holding company that exists for the purpose of holding shares of other companies 16 that manufacture and distribute such products rather than producing or selling its 17 own goods or services. 18

27. Although Defendant ALLERGAN PLC claims its only principal office
 is located at Clonshaugh Business and Technology Park Coolock, Dublin, D17
 E400, Ireland, it maintains headquarters located at Morris Corporate Center III, 400
 Interpace Parkway, Parsippany, New Jersey 07054 and 2525 Dupont Drive, Irvine,
 California 92612.

24 28. As a result of its acquisition of Defendant ALLERGAN, INC. on
25 March 17, 2015, Defendant ALLERGAN PLC expanded its franchises to include
26 medical aesthetics/ dermatology/plastic surgery, which included the BIOCELL
27 Textured Breast Implants.

29. Defendant ALLERGAN, INC. represents itself to the public as a 1 2 multi-specialty health care company focused on developing and commercializing innovative pharmaceuticals, biologics, medical devices and over-the-counter 3 products "that enable people to live life to its full potential – to see more clearly, 4 move more freely and express themselves more fully." Conversely, when 5 convenient, Defendant ALLERGAN, INC. represents that it is a holding company 6 7 with no employees.

30. Defendant ALLERGAN, INC. was established pursuant to the laws of 8 Delaware with its principal executive office located at 2525 Dupont Drive, Irvine, 9 California 92612. Defendant ALLERGAN, INC. is headquartered in California, 10 with both its principal place of business as well as its executive team located 11 primarily, if not entirely, in California. 12

Defendant ALLERGAN PLC utilized Defendant ALLERGAN, INC. 31. 13 in California as its primary agent, appointed subsidiary, and designated entity for 14 the marketing, development, sales, research, distribution, approval, processing, and 15 regulatory approval of products in the medical aesthetics, dermatology, and plastic 16 17 surgery fields, including the BIOCELL Textured Breast Implants. Defendant ALLERGAN PLC was thus operating through Defendant ALLERGAN, INC. with 18 respect to the BIOCELL Textured Breast Implants, and was doing so through 19 Defendant ALLERGAN, INC.'s primary corporate offices in Irvine, California. 20 In fact, while Defendant ALLERGAN, INC. is a wholly owned 21 32. 22 subsidiary of Defendant ALLERGAN PLC, a Management Service Agreement between Defendant ALLERGAN PLC, on the one hand, and Defendants 23 ALLERGAN, INC. and ALLERGAN SALES, LLC, on the other, puts these 24

California entities in charge of Defendant ALLERGAN PLC's executive

management; its strategic direction in terms of business operations, financial goals 26 27

and long-term growth; and its general and administrative services. Thus, Defendant

28

ALLERGAN PLC is the shareholder of the very entities that manage it from
 California.

3 33. On March 23, 2006, Defendant ALLERGAN, INC. completed the
acquisition of INAMED CORPORATION, then a global healthcare company that
developed, manufactured, and marketed breast implants, a range of facial
aesthetics, and obesity intervention products.

7 34. INAMED CORPORATION was the corporate successor to MCGHAN
8 MEDICAL CORPORATION—the original manufacturer of breast implants for
9 plastic and reconstructive surgery—which was incorporated in 1974.

35. INAMED CORPORATION and MCGHAN MEDICAL
 CORPORATION were the entities that sought and received PMAs for a majority of
 the recalled BIOCELL Textured Breast Implants, principally from their California
 headquarters located in Santa Barbara, California.

14

15

16

17

18

36. Defendant ALLERGAN SALES, LLC, a Delaware limited liability company formed on February 25, 2002, was engaged in the business of designing, manufacturing, developing, preparing, processing, inspecting, testing, packaging, promoting, marketing, distributing, labelling, or selling for profit, either directly or indirectly, through an agent, affiliate, predecessor or subsidiary, BIOCELL Textured Breast Implants, and did so in part by extensively targeting, marketing to,

Textured Breast Implants, and did so in part by extensively targeting, marketing to,
packaging, distributing, manufacturing, advertising in, and selling to consumers in
California.

22 37. Along with Defendant ALLERGAN, INC., Defendant ALLERGAN
23 SALES, LLC manages Defendant ALLERGAN PLC's business operations.

38. Defendant ALLERGAN SALES, LLC maintains its principle
executive office at 2525 Dupont Drive, Irvine, California. Defendant ALLERGAN
SALES, LLC's members are Defendant ALLERGAN HOLDCO U.S., INC. and
Defendant ALLERGAN HOLDINGS, INC., both of which are domiciled in
California.

39. Defendant ALLERGAN HOLDCO U.S., INC., is engaged in 1 2 developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for consumers around the world, including ALLERGAN's 3 **BIOCELL** Textured Breast Implants. Defendant ALLERGAN HOLDCO U.S., 4 INC. is principally engaged in being an intermediate holding company between 5 Defendant ALLERGAN, INC. and Defendant ALLERGAN SALES, LLC. As 6 recently as August 20, 2019, Defendant ALLERGAN HOLDCO U.S., INC. 7 represented in its periodic SI-550 form to the California Secretary of State that its 8 principle executive office is in Irvine, California. 9

Defendant ALLERGAN HOLDINGS, INC., is engaged in developing, 40. 10 manufacturing and commercializing branded pharmaceuticals, devices and biologic 11 products for consumers around the world, including ALLERGAN's BIOCELL 12 Textured Breast Implants. Defendant ALLERGAN HOLDINGS, INC. is 13 principally engaged in being an intermediate holding company of between 14 Defendant ALLERGAN, INC. and Defendant ALLERGAN SALES, LLC. 15 Defendant ALLERGAN HOLDINGS, INC. maintains its principle executive office 16 in Irvine, California. 17

41. Additionally, Defendant ALLERGAN HOLDINGS, INC. is the direct
parent company of Allergan Pharmaceuticals Holdings Unlimited Company, which
is the direct parent company of Allergan Costa Rica, S.R.L.—the entity responsible
for actually manufacturing ALLERGAN's BIOCELL Textured Breast Implants at
ALLERGAN's plant in Heredia, Costa Rica.

42. Defendant ALLERGAN USA, INC. was and is a wholly owned
subsidiary of Defendant ALLERGAN SALES, LLC and is a corporation
established pursuant to the laws of Delaware. Defendant ALLERGAN USA, INC.
maintains its principle offices at 5 Giralda Farms, Madison, New Jersey and at 2525
Dupont Drive, Irvine, California.

43. At all relevant times, Defendant ALLERGAN USA INC. was engaged
 in the business of designing, manufacturing, developing, preparing, processing,
 inspecting, testing, packaging, promoting, marketing, distributing, labelling, or
 selling for profit, either directly or indirectly, through an agent, affiliate,
 predecessor or subsidiary, BIOCELL Textured Breast Implants, and did so in part
 by extensively targeting, marketing to, packaging, distributing, manufacturing,
 advertising in, and selling to consumers in California.

44. At all material times, ALLERGAN or its parents and subsidiaries were
engaged in the business of designing, manufacturing, developing, preparing,
processing, inspecting, testing, packaging, promoting, marketing, distributing,
labelling, or selling for profit, either directly or indirectly, through an agent,
affiliate, predecessor, or subsidiary, recalled BIOCELL Textured Breast Implants to
patients for breast augmentation and reconstruction, in the United States including
California, including the following recalled products:

Allergan Natrelle Saline-Filled Breast Implants (formerly McGhan RTV
Saline-Filled Mammary Implant) approved under PMA No. P990074. The
following are the textured styles:

Style 163 – BIOCELL Textured Shaped Full Height, Full Projection Saline Breast Implants

Style 168 – BIOCELL Textured Round Moderate Profile Saline Breast
Implants, also referred to as 168MP (168 Moderate Profile)

22 Style 363 – BIOCELL Textured Shaped Moderate Height, Full Projection

- 23 Saline Breast Implants, Allergan catalog includes 363LF, or 363 Low Height
- 24 Full Projection

25 Style 468 – BIOCELL Textured Shaped Full Height Moderate Projection
26 Saline Breast Implants

27 28

18

1	Allergan Natrelle Silicone-Filled Textured Breast Implants (formerly
2	Inamed Silicone-Filled Breast Implants) approved under PMA No. P020056. The
3	following are the textured styles:
4	Style 110 – BIOCELL Textured Round Moderate Projection Gel Filled
5	Breast Implants
6	Style 115 – BIOCELL Textured Round Midrange Projection Gel Filled
7	Breast Implants
8	Style 120 - BIOCELL Textured Round High Projection Gel Filled Breast
9	Implants
10	Style TRL - Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled
11	Breast Implants
12	Style TRLP - Natrelle Inspira BIOCELL Textured Responsive Silicone-
13	Filled Breast Implants
14	Style TRM - Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled
15	Breast Implants
16	Style TRF - Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled
17	Breast Implants
18	Style TRX - Natrelle Inspira BIOCELL Textured Responsive Silicone-Filled
19	Breast Implants
20	Style TCL – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled
21	Breast Implants
22	Style TCLP – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled
23	Breast Implants
24	Style TCM – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled
25	Breast Implants
26	Style TCF – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled
27	Breast Implants
28	

1	Style TCX – Natrelle Inspira BIOCELL Textured Cohesive Silicone-Filled
2	Breast Implants
3	Style TSL – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast
4	Implants
5	Style TSLP – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast
6	Implants
7	Style TSM – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast
8	Implants
9	Style TSF – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast
10	Implants
11	Style TSX – Natrelle BIOCELL Textured Soft Touch Silicone-Filled Breast
12	Implants
13	Natrelle 410 Highly Cohesive Anatomically Shaped Silicone Filled Breast
14	Implants approved under PMA No. P040046. The following are the textured
15	styles:
16	Style 410FM
17	Style 410FF
18	Style 410MM
19	Style 410MF
20	Style 410FL
21	Style 410ML
22	Style 410LL
23	Style 410LM
24	Style 410LF
25	Style 410FX
26	Style 410MX
27	
	Style 410LX
28	Style 410LX

1	Allergan Tissue Expanders for the breast that have BioCell texturing	
2	originally cleared for commercial distribution under Section 510(k):	
3	Natrelle 133 Plus Tissue Expander (K143354)	
4	Natrelle 133 Tissue Expander with Suture Tabs (K102806)	
5	(Collectively, "BIOCELL Textured Breast Implants")	
6	45. Plaintiff is unaware of the true names and capacities of the remaining	
7	defendants sued in this action by the fictitious names DOES 1 through 100. Plaintiff	
8	will amend this complaint when those names and/or capacities become known to	
9	Plaintiff. Plaintiff is informed and believe that each of the fictitiously named	
10	defendants is in some manner responsible for the events and allegations set forth in	
11	this complaint.	
12	46. At all relevant times, defendants, and each of them, were the agents	
13	and employees of each of the remaining defendants, and were at all times acting	
14	within the purpose and scope of said agency and employment, and each defendant	
15	has ratified and approved the acts of its agents.	
16		
17	VENUE AND JURISDICTION	
18	47. Venue is proper in this District pursuant to 28 U.S.C. §1391(b)(1)	
19	because all Defendants reside in the Central District of California. Venue is proper	
20	in this District pursuant to 28 U.S.C. §1391(b)(2) because a substantial part of the	
21	events or omissions giving rise to this action occurred within the Central District of	
22	California. Venue also is proper pursuant to 28 U.S.C. §1391(c)(2) because this	
23	Court maintains personal jurisdiction over Defendants.	
24	48. This action is a "diversity of citizenship" action as defined by 28	
25	U.S.C. § 1332(a). This Court has subject matter jurisdiction because: (1) the	
26	amount in controversy exceeds the sum or value of \$75,000, exclusive of interest	
27	and costs; and (2) Plaintiff is a citizen of a state different than one or more	
28	Defendants.	

A. All Of The Named ALLERGAN Defendants Are "At Home" In California

49. ALLERGAN has past, present, ongoing, and continuing contacts with 3 the State of California and the County of Orange by designing, formulating, testing, 4 packaging, labeling, producing, creating, constructing, making, assembling, 5 advertising, clinical testing, marketing, promoting, distributing, manufacturing, 6 7 importing, and selling consumer products, including the BIOCELL Textured Breast Implants, in this state and county with the reasonable expectation and knowledge 8 that they will be thereafter be distributed across the state, across the country, and 9 throughout the world. 10

50. Accordingly, ALLERGAN has past, present, ongoing, and continuing
contacts with California by transacting substantial and regular business in this state
and manufacturing, distributing, and/or selling goods with the reasonable
expectation and knowledge that they will be used in this state, across the country,
and throughout the world. Such contacts are so continuous and systematic as to
render ALLERGAN at home in California.

17

1

2

18

1. ALLERGAN consistently identifies Irvine, California as the location of its primary worldwide business office

19 51. California law requires all corporations, limited liability companies
20 and common interest development associations to update the records of the
21 California Secretary of State either every year or every two years based on year of
22 registration by filing a Form SI-550, which amongst other items, requires entities to
23 identify the location of its principal executive office, i.e. its primary worldwide
24 business office, or the "nerve center" of the corporation. ALLERGAN's filings
25 indicate the following:

26 27

27 28 Defendant ALLERGAN, INC.'s November 22, 2019 filing identifies its principal executive office as being located at 2525 Dupont Drive, Irvine, CA 92612;

1	b.	Defendant ALLERGAN HOLDCO US, INC.'s August 20, 2019 filing
2		identifies its principal executive office as being located at 18581 Teller
3		Avenue, Irvine, CA 92612;
4	с.	Defendant ALLERGAN HOLDINGS, INC.'s January 7, 2020 filing
5		identifies its principal executive office as being located at 2525
6		Dupont Drive, Irvine, CA 92612;
7	d.	Until November 14, 2017, Defendant ALLERGAN USA, INC.'s
8		principal executive office was located at 2525 Dupont Drive, Irvine,
9		CA 92612 and had been such since 2007; and
10	e.	Until June 20, 2018, Defendant ALLERGAN SALES, LLC's principal
11		executive office was located at 2525 Dupont Drive, Irvine, CA 92612
12		and had been such since 2002.
13	2.	ALLERGAN's claims that its entities are located in New Jersey
14		are disingenuous
15	52.	On September 26, 2018, in the matter captioned Pamela Shelp et al.
16	vs. Allerga	n, Inc. et al, 2:18-cv-1427 (W.D. Wash.) the Assistant Secretary of
17	Defendant	ALLERGAN SALES, LLC, Judith W. Tomkins, submitted a declaration
18	under the p	enalty of perjury in support of a notice of removal whereby she
19	declared:	
20	a.	"Allergan USA, Inc. is a Delaware corporation with its principal place
21		of business located in New Jersey;
22	b.	Allergan, Inc. is a Delaware corporation that is a holding company
23		with no employees. To the extent Allergan, Inc. could be said to have a
24		principal place of business, it would not be in Washington.
25	с.	Allergan Sales, LLC is a limited liability company formed in the state
26		of Delaware. Allergan Sales, LLC's members are Allergan Holdco
27		U.S., Inc. and Allergan Holdings, Inc., both of which were
28		incorporated in Delaware and are domiciled in California.
		-17-

1	d. Allergan plc is a public limited company formed and organized outsid	le
2	of the United States with its principal place of business located in	
3	Dublin, Ireland and with its U.S. administrative offices in New	
4	Jersey."	
5	53. Ten months later, on July 30, 2019, in the matter captioned <i>In re:</i>	
6	National Prescription Opiate Litigation, No. 1:2017-md-02804 (N.D.O.H)	
7	Defendants ALLERGAN PLC, ALLERGAN SALES, LLC, and ALLERGAN	
8	USA, INC. submit the expert report of Professor Jonathan R. Macey-the Sam	
9	Harris Professor of Corporate Law, Corporate Finance, and Securities Law at Yale	
10	Law School, and Professor in the Yale School of Management. Professor Macey	
11	reports having more than 30 years of experience in the area of corporate	
12	governance. Professor Macey further states that in the process of preparing his	
13	report he examined the relationships among the ALLERGAN entities from a	
14	corporate governance perspective. Importantly, he concludes:	
15	a. " <u>Allergan Sales, LLC</u> . Defendant Allergan Sales, LLC was formed in	
16	Delaware and is headquartered in Irvine, California.	
17	b. <u>Allergan USA, Inc</u> . Defendant Allergan USA, Inc. is incorporated in	
18	Delaware and headquartered in Irvine, California."	
19	54. Three months later, on November 1, 2019, in the matter captioned <i>In</i>	
20	re: Allergan Biocell Textured Breast Implant Litigation, MDL No. 2921,	
21	Defendants ALLERGAN, INC. and ALLERGAN USA, INC. file a response to a	
22	motion to transfer and centralization of the related proposed class actions. As part	
23	of their response, Defendants ALLERGAN, INC. and ALLERGAN USA, INC.	
24	make the dubious claim: "The District of New Jersey is where Allergan is located.	
25	Allergan USA, Inc. is headquartered and has its principal place of business in New	
26	Jersey."	
27	55. ALLERGAN has a pattern and practice of making conflicting	
28	representations of where its entities are located for the purposes of evading	
	-18-	

litigation and escaping the jurisdiction of courts across the country. The equitable
 and just result demands that the ALLERGAN entities be held to be at home in all of
 these locations, including Orange County, California.

5 6 7

25

26

27

28

4

3. Defendant ALLERGAN PLC is merely the alter-ego of Defendants ALLERGAN, INC. and ALLERGAN SALES, LLC such that it too is at home in Irvine, California

56. On September 7, 2017, in the matter captioned *State of Ohio vs.* Purdue Pharma L.P., et al., No. CV-17 CI 000261-one of the seminal prescription 8 opioid cases where Defendant ALLERGAN PLC was accused of, amongst other 9 things, deliberately maintaining deficient suspicious order monitoring system 10 protocols that enabled the distribution of billions of opioid pills nationally—the 11 Senior Vice President and Chief Accounting Officer at Defendant ALLERGAN 12 PLC, James C. D'Arecca, submitted a declaration under the penalty of perjury in 13 support of a motion to dismiss for lack of personal jurisdiction whereby he 14 declared: 15

- a. "Allergan plc f/k/a Actavis plc ("Allergan plc") is a corporation
 incorporated under the laws of the Republic of Ireland. Allergan plc's
 headquarters, and its only offices, are located in Ireland [...]
- b. Allergan plc is a holding company that exists for the purpose of
 holding shares of other companies that manufacture and distribute
 prescription drugs rather than producing its own goods or services [...
 .] Allergan plc also does not manufacture any goods or sell any
 products (including Kadian® or other opioids) or services either in the
 United States or anywhere else in the world [...]

c. Allergan plc is not registered to do business anywhere in the United States. Allergan plc does not now conduct and has never conducted any business operations in the United States. Allergan plc does not lease or own any offices or facilities in the United States, and it has no

employees in the United States (other than certain corporate officers 1 and members of its Board of Directors who reside in the United 2 States). The administrative offices in the United States referenced on 3 Allergan.com are not owned or leased by Allergan plc [...] 4 d. Allergan plc does not currently and has never manufactured, 5 distributed, marketed, promoted, or sold any pharmaceutical products 6 (including Kadian[®]) in the United States." 7 57. However, it was later revealed in that action that Defendant 8 ALLERGAN PLC's top executives live in the United States and a vast majority of 9 its profits are generated in the United States. In fact, Defendant ALLERGAN PLC 10 does not maintain its own tax group separate from Defendant ALLERGAN SALES, 11 LLC, and Defendant ALLERGAN SALES, LLC employs and pays Defendant 12 ALLERGAN PLC's executive officers. 13 58. Moreover, while Defendants ALLERGAN, INC. and ALLERGAN 14 SALES, LLC are wholly owned subsidiaries of Defendant ALLERGAN PLC, a 15 Management Service Agreement between Defendant ALLERGAN PLC, on the one 16 17 hand, and Defendants ALLERGAN, INC. and ALLERGAN SALES, LLC, on the other, puts these California entities in charge of Defendant ALLERGAN PLC's 18 executive management; its strategic direction in terms of business operations, 19 20 financial goals and long-term growth; and its general and administrative services. Thus, Defendant ALLERGAN PLC is the shareholder of the very entities that 21 22 manage it from California. 59. It is clear the ALLERGAN entities attempt to abuse the corporate form 23 to obfuscate ALLERGAN's corporate hierarchy for the purposes of insolating 24 Defendant ALLERGAN PLC from jurisdictional reach of courts in the United 25 States and thereby avoiding liability. Thus, again, the equitable and just result 26 demands that Defendant ALLERGAN PLC be held to be at home in the location of 27 the entities that control it—which is Irvine, California. 28

1 Alternatively, This Court Has Specific Jurisdiction Over The Named **B**. 2 **ALLERGAN Defendants** 3 This Court has specific personal jurisdiction over the parties to this 60. 4 civil action because BIOCELL Textured Breast Implants that were implanted in 5 Plaintiff were researched, designed, tested, labeled, marketed, promoted, 6 7 distributed, and sold from this forum, regulatory compliance and postmarket surveillance was orchestrated from this forum, and ALLERGAN has purposefully 8 availed itself of the privileges and benefits of doing business in California. 9 1. Pursuant to federal law, ALLERGAN identifies Irvine, California 10 as the location of the entities "directly responsible" the production 11 and distribution of all BIOCELL Textured Breast Implants in the 12 **United States** 13 61. Owners or operators of places of business (also called establishments 14 or facilities) that are involved in the production and distribution of medical devices 15 intended for use in the United States are required to register annually with the FDA. 16 17 This process is known as establishment registration. Pursuant to 21 C.F.R. 807.20(a), the registration and listing requirements pertain to any entity engaged in 18 the manufacture, preparation, propagation, compounding, assembly, or processing 19 of a device intended for human use, including any person who: 20 initiates or develops specifications for a device that is to be 21 a. manufactured by a second party; 22 b. sterilizes or otherwise makes a device for or on behalf of a 23 specifications developer or any other person; 24 repackages or relabels a device; 25 c. d. reprocesses a single use device that has previously been used on a 26 27 patient; acts as an initial importer. 28 e. -21-COMPLAINT AND DEMAND FOR JURY TRIAL

62. The FDA's Establishment Registration & Device Listing for the 1 BIOCELL Textured Breast Implants identifies the establishment specification 2 developer for these implants as Defendant ALLERGAN SALES, LLC with a 3 corresponding address of 2525 Dupont Drive, Irvine, California 92612 with a date 4 of registration of 2020.⁴ The listing further identifies ALLERGAN SALES, LLC as 5 the initial distributor/importer of these implants. 6 Moreover, the identified owner/operator is Defendant ALLERGAN, 63. 7

8 INC. with a corresponding address of 2525 Dupont Drive, Irvine, California
9 92612.⁵

64. The listed official correspondent identifies ALLERGAN's Director of
 Regulatory Information Management, David J. Fisher, with a corresponding
 address of 2525 Dupont Drive, Irvine, California 92612 and telephone number 714 246-3862.⁶

14 65. The FDA's Establishment Registration & Device Listing for the
15 BIOCELL Textured Breast Implants identifies the establishment manufacturer for
16 these implants ambiguously as Allergan—presumably referring to Allergan Costa
17 Rica, S.R.L., the subsidiary of the California entity Defendant ALLERGAN

- 18
- ¹⁹ ⁴ Pursuant to 21 C.F.R. 807.3(c), "[e]stablishment means a place of business under
 one management at one general physical location at which a device is
 manufactured, assembled, or otherwise processed."
- ⁵ Pursuant to 21 C.F.R. 807.3(f), "[o]wner or operator means the corporation,
 subsidiary, affiliated company, partnership, or proprietor directly responsible for
 the activities of the registering establishment."
- ²³ the activities of the registering establishment.
 ⁶ Pursuant to 21 C.F.R. 807.3(e), "[o]fficial correspondent means the person designated by the owner or operator of an establishment as responsible for the following: (1) The annual registration of the establishment; (2) Contact with the
- Food and Drug Administration for device listing; (3) Maintenance and submission
- of a current list of officers and directors to the Food and Drug Administration upon
 the request of the Commissioner; and (4) The receipt of pertinent correspondence
- 28 from the Food and Drug Administration directed to and involving the owner or operator and/or any of the firm's establishments."

HOLDINGS, INC.—with a corresponding address of 900 Parkway Global Park, La 1 Aurora De Heredia, Heredia, Costa Rica with a date of registration of 2020. 2 66. The manufacture listing further identifies the owner/operator as 3 Defendant ALLERGAN, INC. with a corresponding address of 2525 Dupont Drive, 4 Irvine, California 92612. 5 The listed official correspondent identifies ALLERGAN's Director of 67. 6 Regulatory Information Management, David J. Fisher, with a corresponding 7 address of 2525 Dupont Drive, Irvine, California 92612 and telephone number 714-8 246-3862. 9 68. The designated US Agent is ALLERGAN's Executive Director for 10 Regulatory Affairs for Devices and Combination Products, James Wabby, with a 11 12 corresponding address of 2525 Dupont Drive, Irvine, California 92612 and telephone number 714-246-2259.⁷ 13 Further, the applicant addresses for each of the PMAs and the PMA 69. 14 supplements for the BIOCELL Textured Breast Implants lists ALLERGAN's 15 business office in Irvine, California.⁸ 16 The FDA identifies the "Recalling Firm/Manufacturer" for the 17 70. **BIOCELL** Textured Breast Implants Class 1 Device Recall as Defendant 18 ALLERGAN PLC with a corresponding address of 2525 Dupont Dr., Irvine, CA 19 92612.⁹ 20 21 22 ⁷ Pursuant to 21 C.F.R. 807.3(s), "United States agent means a person residing or 23 maintaining a place of business in the United States whom a foreign establishment 24 designates as its agent." ⁸ https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P990074; 25 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020056; 26 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040046; 27 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K143354; https://www.accessdata.fda.gov/scrIpts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K102806. 28 ⁹ https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=175502. -23-COMPLAINT AND DEMAND FOR JURY TRIAL

Thus, there is no disputing that the named ALLERGAN entities
 engaged in and were responsible for the importation, manufacture, preparation,
 propagation, compounding, assembly, or processing of the BIOCELL Textured
 Breast Implants are all basing their operation in Irvine, California.

2. ALLERGAN's additional California contacts regarding the development, production and distribution of *all* BIOCELL Textured Breast Implants across the United States run deep

8 72. In addition to representing to the U.S. Government that all things
9 related to the national production and distribution of the BIOCELL Textured Breast
10 Implants are orchestrated from Irvine, California, ALLERGAN has additional
11 California contacts related to the BIOCELL Textured Breast Implants such that it
12 has purposefully availed itself of the privileges and benefits of doing business in
13 California. Those minimum contacts and purposeful availment consist, at least in
14 part, of the following:

- a. ALLERGAN's predecessor corporations, INAMED CORPORATION
 and MCGHAN MEDICAL CORPORATION conducted product
 development, executive functioning, and legal compliance for all of
 the recalled BIOCELL Textured Breast Implants in its California
 headquarters in Santa Barbara County.
 - b. ALLERGAN, INAMED CORPORATION and MCGHAN MEDICAL CORPORATION organized clinical studies concerning the BIOCELL Textured Breast Implants across the state, including in Santa Barbara, Goleta, Carpinteria, Irvine, and Campbell, California.
- c. On information and belief, ALLERGAN's predecessor corporation,
 MCGHAN MEDICAL CORPORATION, purchased, license, or
 otherwise acquired the rights to use the BIOCELL texturization
 process from two residents of Santa Barbara, California.
- 28

20

21

22

23

5

6

1	d.	Until 2014, just prior to its acquisition by Activis plc, ALLERGAN
2		maintained a facility in Santa Barbara, California that served as the
3		center of its breast implant research and development. Thereafter, the
4		breast implant research team was located to ALLERGAN's facilities in
5		Irvine, CA.
6	e.	The consignee identified on import bills of lading for ALLERGAN
7		breast implant prostheses from ALLERGAN's manufacturing plant in
8		Heredia, Costa Rica is Defendant ALLERGAN USA, INC. or
9		ambiguously Allergan, with a corresponding address of 18655 Teller
10		Avenue, Irvine, California, 92612.
11	f.	The United States Patent and Trademark Office identifies the registrant
12		of the BIOCELL trademark as MCGHAN MEDICAL
13		CORPORATION with a corresponding address of 700 Ward Drive,
14		Santa Barbara, California 93111. The current listed owner identified is
15		Defendant ALLERGAN, INC. with a corresponding address of 2525
16		Dupont Drive, Irvine, California 92612.
17	g.	ALLERGAN's medical aesthetics division responsible for design/
18		development, clinical operation, data analysis and regulatory affairs
19		for its breast implant products, including the BIOCELL Textured
20		Breast Implants Class 1 Device Recall, is based in its Irvine, California
21		headquarters.
22	h.	ALLERGAN has been repeatedly haled into court in California for
23		issues related to its implantable breast protheses. In those matters,
24		ALLERGAN voluntarily accepted service of summons, and
25		voluntarily consented to the personal jurisdiction of California for the
26		injuries resulting from the implantation of its products. It actively
27		litigated those cases, serving and answering discovery, filing motions,
28		attending mediations, and settling claims against it.
	1	

1	i.	The FDA's November 17-20, 2003 establishment inspection
2		concerning the BIOCELL Textured Breast Implants occurred at
3		ALLERGAN's, then INAMED CORPORATION's, headquarters at 71
4		South Los Carneros Road, Goleta, CA 93117. That inspection focused
5		on the monitoring activities for both the investigational device
6		exemption study and adjunct clinical studies of ALLERGAN's
7		silicone gel-filled breast implants. A complaint regarding lack of
8		monitoring and oversight of clinical investigators involved in the
9		adjunct study was also investigated.
10	j.	The FDA's February 16-18, 2005 establishment inspection concerning
11		the BIOCELL Textured Breast Implants occurred at INAMED
12		CORPORATION's headquarters at 71 South Los Carneros Road,
13		Goleta, CA 93117. This inspection focused on the ALLERGAN's
14		Style 410 silicone gel-filled breast implants study, accountability
15		practices for the adjunct study were also covered and resulted in the
16		issuance of an FDA-483 for having 7,065 devices with unknown
17		status.
18	k.	The FDA's April 4-6, 2007 establishment inspection, the first
19		inspection following ALLERGAN's acquisition of INAMED
20		CORPORATION, concerning the BIOCELL Textured Breast Implants
21		occurred at ALLERGAN's offices at 71 South Los Carneros Road,
22		Goleta, CA 93117. The inspectors noted that while "Allergan's
23		corporate offices are located at 2525 Dupont Drive, Irvine, California
24		92612 [a]ll manufacturing operations for silicone and saline breast
25		implants and tissue expanders are performed at Allergan's facility in
26		Ireland. Complaints and MDRs for this product are handled at the
27		Goleta, California facility."
28		

1	1.	The FDA's August 9-12, 2011 establishment inspection concerning the
2		BIOCELL Textured Breast Implants occurred at ALLERGAN's
3		offices at 71 South Los Carneros Road, Goleta, CA 93117. Again,
4		inspectors noted that while "Allergan's corporate offices are located at
5		2525 Dupont Drive, Irvine, California 92612 [a]ll manufacturing
6		operations for silicone and saline breast implants and tissue expanders
7		are performed at Allergan's facility in Ireland. Complaints and MDRs
8		for this product are handled at the Goleta, California facility."
9		Moreover, "[t]he Santa Barbara facility is a corporate office where
10		specifications are developed and complaint & MDR activities are
11		performed."
12	m.	The FDA's February 5-6, 2014 establishment inspection concerning
13		the BIOCELL Textured Breast Implants occurred at ALLERGAN's
14		offices at 71 South Los Carneros Road, Goleta, CA 93117. Inspectors
15		noted that the upper managers for ALLERGAN "are located at
16		Allergan's headquarters, 2525 Dupont Drive, Irvine, CA 92612." The
17		report further states:
18		i. The inspected Goleta site does no manufacturing of any finished
19		medical device or any components to a medical device. It is
20		registered as a specification developer because it is responsible
21		for design controls for most of the aesthetic devices, including
22		the BIOCELL Textured Breast Implants.
23		ii. It is registered as a manufacturer because it is responsible for
24		determining if a complaint investigation is required, conducts
25		the failure analysis of retuned breast implants, and reports
26		MDRs and PSRs.
27		iii. Goleta makes the decision whether a complaint needs to be
28		investigated and if it needs to be reported as an MDR.
		27

1	iv. Returned breast implants and explants are analyzed at the Goleta
2	facility.
3	n. The most recent Establishment Inspection Report performed by FDA
4	Supervisory Consumer Safety Officers on October 19, 2016 for the
5	recalled BIOCELL Textured Breast Implants occurred at the 2525
6	Dupont Drive, Irvine, California headquarters. Importantly, the name
7	and address of the appropriate ALLERGAN employee for all FDA
8	official correspondence regarding BIOCELL Textured Breast Implants
9	was Defendant ALLERGAN PLC's CEO/President Mr. Brent
10	Saunders with a corresponding address of 2525 Dupont Dr., Irvine, CA
11	92612. The report further states:
12	i. This Irvine facility performs design/development, clinical
13	operation, data analysis and regulatory affairs.
14	ii. The firm is registered with the FDA as a specification developer
15	and importer.
16	iii. That while the firm was acquired by Actavis Plc in 2015, the
17	legal name of the facility remains unchanged as Allergan, Inc.
18	73. At all times material hereto, Defendants maintained systematic and
19	continuous contacts in this judicial district, regularly transacted business within this
20	judicial district, employed numerous individuals in this district and regularly
21	availed themselves of the benefits of this judicial district. Defendants received
22	substantial financial benefit and profits as a result of the designing, formulating,
23	testing, packaging, labeling, producing, creating, constructing, making, assembling,
24	advertising, clinical testing, marketing, promoting, distributing, manufacturing, and
25	selling BIOCELL Textured Breast Implants in this state and county, and throughout
26	the United States. Defendants promoted, sold, distributed, made, assembled,
27	marketed, advertised, and promoted the BIOCELL Textured Breast Implants in
28	California with those products ultimately causing harm across the United States.

74. At all times material hereto, the action arises from obligations that
 arise out of, or are connected with, Defendants' activities within the State of
 California.

4

5

6

7

23

24

25

26

27

28

75. Plaintiff is informed and believes and, on that basis alleges that Defendants have purposefully directed their activities at this forum State and the exercise of jurisdiction is reasonable and would not offend the traditional notions of fair play and substantial justice.

8 76. Plaintiff is informed and believes and, on that basis, alleges that
9 Defendants have purposefully availed themselves of the privileges and benefits of
10 conducting activities and business within the forum State, and have invoked the
11 benefits and protections of its laws.

12 77. Accordingly, a substantial part of the events giving rise to Plaintiff's
13 claims occurred in California, including federal and state regulatory compliance,
14 the preparation and submission of the relevant product PMAs, and communication
15 regarding the product, the design, formulation, testing, packaging, labeling,
16 production, creation, construction, making, assembly, advertising, clinical testing,
17 marketing, promotion, distribution, manufacturing, and selling of the BIOCELL
18 Textured Breast Implants.

19 78. Thus, none of the named ALLERGAN Defendants can deny this Court
20 has specific personal jurisdiction over the parties to this civil action because
21 ALLERGAN has purposefully availed itself of the privileges and benefits of doing
22 business in California.

-29-

GENERAL ALLEGATIONS 1 **Federal Law and Requirements** A. 2 79. The Medical Device Amendments of 1976 (MDA), 21 U.S.C. 360c et 3 seq., to the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. 301 et seq., 4 impose a regime of detailed federal oversight administered by the FDA for medical 5 devices. Depending on the nature of the device and the risks it presents, that 6 7 oversight ranges from general federal regulations governing the labeling and manufacture of all medical devices, to a rigorous regime of premarket approval for 8 certain devices. 9 80. FDA may grant premarket approval ("PMA") for a device only if it 10 finds, among other things, that (a) there is "reasonable assurance" of the device's 11 "safety and effectiveness" under the conditions of use included in the proposed 12 labeling, and (b) the proposed labeling is neither false nor misleading. 21 U.S.C. 13 360e(d)(1)(A), (2)(A), (B) and (D). After premarket approval, a manufacturer 14 generally must receive FDA's approval of a supplemental application before 15 making any change to the device itself that would affect its safety or effectiveness. 16 See 21 U.S.C. 360e(d)(6)(A)(i); 21 C.F.R. § 814.39(a). 17 PMA is specific to individual devices, but such devices are thereafter 81. 18 also subject to the more general provisions of the MDA and FDA's regulations. Of 19 particular importance are the requirements that a medical device manufacturer: 20 Collect and report to the FDA within certain timeframes information 21 (a) on certain adverse events associated with its device. See 21 U.S.C. 22 360i(a); 21 C.F.R. Part 803. 23 (b) Implement quality systems and current good manufacturing practices 24 with respect to the device. See 21 U.S.C. 351(h); 21 C.F.R. Part 820. 25 82. Additionally, within the MDA exists an express preemption provision 26 applicable to PMA devices which states: 27 28

1	[N]o State or political subdivision of a State may establish or continue in
2	effect with respect to a device intended for human use any requirement -
3	(1) which is different from, or in addition to, any requirement
4	applicable under [the FDCA] to the device, and
5	(2) which relates to the safety or effectiveness of the device or to any
6	other matter included in a requirement applicable to the device under
7	[the FDCA]. 21 U.S.C. 360k(a).
8	1. No express preemption of state-law claims paralleling MDA and
9	federal regulatory requirements
10	83. As set forth in the MDA's express preemption provision, a state
11	requirement is preempted only if it is "different from, or in addition to," federal
12	requirements. 21 U.S.C. 360k(a)(1). Through that qualification, Section 360k(a)
13	permits a State to provide a traditional damages remedy for violations of common-
14	law duties when those duties parallel federal requirements. ¹⁰
15	84. For example, where both the FDCA (as implemented by FDA) and
16	State law require a manufacture to deliver warnings regarding its device through an
17	appropriate channel—such as the FDA—those duties are parallel such that
18	preemption is inapplicable. That parallelism is reinforced by the FDCA's command
19	that either inadequate warnings (21 U.S.C. 352(f)(2)) or a failure to submit required
20	adverse event reports to FDA (21 U.S.C. 352(r)(2), 360i(a)) will render a device
21	misbranded, and therefore "prohibited [from] introduction or delivery for
22	introduction into interstate commerce." 21 U.S.C. 331(a).
23	85. As the Ninth Circuit reasoned in <i>Stengel v. Medtronic Inc.</i> , such a
24	"claim rests on a state-law duty that parallels a federal-law duty under the MDA
25	10 A - the Country Country to the Discoular Malterenia Inc. (18 2001, does not
26	¹⁰ As the Supreme Court stated in <i>Riegel v. Medtronic, Inc.</i> , "§ 360k does not prevent a State from providing a damages remedy for claims premised on a
27	violation of FDA regulations; the state duties in such a case 'parallel,' rather than
28	add to, federal requirements." (2008) 553 U.S. 312, 330 (citing <i>Medtronic, Inc. v. Lohr</i> (1996) 518 U.S. 470, 495).

...." 704 F.3d 1224, 1233 (2013) (en banc). Specifically, the plaintiff alleged that
 the manufacturer's failure to warn the FDA of adverse health consequences
 constituted a violation of both the MDR requirements and the general duty of
 reasonable care under State law, which includes a duty to warn. *Ibid*.

5

6

7

8

9

10

86. This is because the MDR regulations are related to the manufacturer's duty to provide the FDA with information regarding a device's safety and effectiveness, and this information is disseminated to the public. Manufacturers provide these reports to the FDA, the FDA then disseminates the reports to the public, and the reports are then relied upon by physicians and authors of medical journals in comparing the relative safety of medical devices.

87. Likewise, California imposes a duty on manufacturers to warn of 11 potential risks or dangers of their products, which sounds in both negligence and 12 strict liability. See Carlin v. Superior Court (1996) 13 Cal.4th 1104, 1110-1112. 13 This is a continuing duty that lasts as long as the product is in use. Valentine v. 14 Baxter Healthcare Corp. (1999) 68 Cal.App.4th 1467, 1482; see also CACI Nos. 15 1205, 1222. The state-law duty to warn may in some circumstances be satisfied by 16 giving the information to a third party who can reasonably be relied on to convey 17 the danger. Persons v. Salomon North America, Inc. (1990) 217 Cal.App.3d 168, 18 175-178. California follows the Restatement Second of Torts standard for a 19 manufacturer's reasonable reliance on an intermediary to convey warnings. Id. at 20 175 (adopting Restatement Second of Torts, § 388, com. n). The focus of this 21 22 standard is whether, in light of all the circumstances, a manufacturer or supplier acted reasonably in relying on a third party to pass warnings on to the ultimate user. 23 Id. at 175-178. 24

88. Thus, a factfinder could infer that a manufacturer's failure to provide
information regarding a device's safety and effectiveness as required by FDA
regulations is a parallel violation of the state duty to provide reasonable and
adequate information about a device's risks.

89. This parallelism is reinforced under California's doctrine of negligence 1 per se where the failure to exercise due care is presumed from a violation of a 2 "statute, ordinance, or regulation of a public entity." Cal. Evid. Code, § 669(a)(1). 3 By its terms, this doctrine applies to the law of any public entity, not just California 4 public entities. See, e.g., DiRosa v. Showa Denko K.K. (1996) 44 Cal.App.4th 799, 5 808. Thus, under California law, a money damages remedy exists for negligent 6 7 violation of the FDCA and regulations promulgated thereunder which proximately cause injuries, and there is no need for California's Legislature to act in order to 8 create such a remedy. 9

90. The foregoing principles refute any anticipated contention by 10 ALLERGAN that Section 360k(a) expressly preempts Plaintiff's state law claims 11 set forth below. Under Riegel v. Medtronic, Inc. (2008) 552 U.S. 312, the U.S. 12 Supreme Court held the premarket approval of the plaintiff's device established 13 preemptive requirements with respect to the design and labeling of the device. 14 Those would preempt any claim alleging in substance that FDA should have 15 conditioned its approval on adopting some other design or labeling. Such were the 16 17 nature of the claims at issue in *Riegel*, and those claims were therefore preempted.

91. But where, as here, a plaintiff's claims are based on conduct *after* a
device received premarket approval, that conduct is governed not by the terms of
the device's premarket approval, but rather by FDA's general regulations governing
medical devices generally. Accordingly, state law claims—whether styled as arising
from a failure to make adverse event reports to FDA or from a failure to maintain
appropriate quality control systems—are not expressly preempted.

24

2.

25

No implied preemption of state-law claims premised on violations of the MDA and federal regulatory requirements

92. Where a plaintiff alleges that a defendant had made fraudulent
misrepresentations to the FDA in the course of obtaining premarket approval for a
medical device, such "fraud on-the-FDA claims" are impliedly preempted because

they conflict with the FDA's responsibility to police fraud on the agency and they
 seek to enforce an exclusively federal requirement not grounded in traditional tort
 law. *Buckman Co. v. Plaintiffs' Legal Comm.* (2001) 531 U.S. 341, 348-353.

Central to the doctrine of implied preemption is that a state law claim 93. 4 cannot exist solely by virtue of the federal enactments-State law has no role to 5 play in policing the relationship between a federal agency and the entity it 6 7 regulates. Conversely, claims relying on traditional State tort law which had predated the federal enactments in question are unaffected. Therefore, a claim 8 against a device manufacturer is viable if the plaintiff is suing for conduct that 9 violates the FDCA (or else her claim is expressly preempted by Section 360k(a)), 10 but the plaintiff must not be suing because the conduct violates the FDCA (such a 11 claim would be impliedly preempted under Buckman). 12

94. Thus, as recognized in Stengel, a manufacturer's failure to report, for 13 example, is more than a mere misrepresentation to the FDA because it 14 simultaneously misled the device's current and potential users, to whom the 15 manufacturer owed an independent duty under state law. Thus, such claims are 16 17 grounded in a traditional category of state law failure-to-warn claims that predate the federal enactments in question, and the claims therefore do not exist solely by 18 virtue of those enactments. As a result, such claims are not impliedly preempted by 19 the MDA. 20

21

22 23 **B**.

Statement of Facts Relating to Preemption Applicable to Plaintiff's Failure to Warn and Negligence Claims

24 95. All three generations of the recalled BIOCELL Textured Breast
25 Implants received premarket approval under PMA Order Nos. P990074 (2000),
26 P020056 (2006), and P040046 (2013).

96. In 2011 and in 2015, the recalled Natrelle 133 Plus Tissue Expander
 (K143354) and Natrelle 133 Tissue Expander with Suture Tabs (K102806) were
 approved for sale under section 510(k), respectively.¹¹

97. Under federal law and regulation, Allergan was under a continuing
duty to monitor its BIOCELL Textured Breast Implants after premarket approval
and to discover and report to the FDA any complaints about the device's
performance and any adverse health consequences of which it became aware and
that are or may be attributable to its BIOCELL Textured Breast Implants. See 21
C.F.R. § 803.50 *et seq*; 21 C.F.R. § 820.198(a)(3); 21 U.S.C. 360i.

98. Pursuant to these regulations, ALLERGAN was obligated to file
 within a mandatory timeframe detailed medical device reports (MDRs) for *all* BIA ALCL events related to its BIOCELL Textured Breast Implants that it had
 knowledge of, foreign or domestic, and this includes any event that could
 reasonably be interpreted as possible BIA-ALCL given the nature of the facility,
 doctor or patient complaint.

16 99. Notwithstanding this obligation, ALLERGAN failed to investigate
17 complaints of adverse events and submit such adverse events concerning the
18 BIOCELL Textured Breast Implants as MDRs in violation of general medical
19 device regulations designed to ensure patient safety.

20 100. As a result, Allergan failed to properly perform its duties and failed to
21 inform the FDA of the increased risk of BIA-ALCL associated with its BIOCELL

¹¹ A medical device marketed after the MDA's effective date may bypass the PMA process if the device is "substantially equivalent" to a "grandfathered" pre-MDA device (i.e., a device approved prior to 1976). This exception to premarket approval is known as the "510(k)" process and simply requires the manufacturer to notify the FDA under section 510(k) of the MDA of its intent to market a device, and to explain the device's substantial equivalence to a pre-MDA predicate device. The FDA may then approve the new device for sale in the United States. *The MDA does not require an FDA determination that the device is, in fact, substantially equivalent to a grandfathered device.*

Textured Breast Implants using medical device reports; even though it should have
 been aware of the many adverse events that did occur and was actually aware of
 these adverse events—but failed to file medical device reports pursuant to 21
 C.F.R. Part 803; 21 C.F.R. § 820.198; and 21 U.S.C. 360i.

- 5 6
- 7

1. ALLERGAN violated 21 C.F.R. § 803.50 *et seq* by failing to file MDRs following receipt of both foreign and domestic complaints of BIA-ALCL

8 101. A manufacturer must report adverse events no later than 30 calendar
9 days after the day that it received or otherwise become aware of information, *from*10 *any source*, that reasonably suggests that a device may have caused or contributed
11 to a death or serious injury, or malfunctioned. 21 C.F.R. § 803.50 (emphasis
12 added).

102. This reporting duty is triggered not just for events occurring within the 13 United State and its territories, but also adverse events occurring in a foreign 14 country concerning the device. Under the FDA's Medical Device Reporting for 15 Manufacturers Guidance for Industry, the FDA considers an event that occurs in a 16 17 foreign country reportable under the MDR regulations if it involves a device that has been cleared or approved in the United States- or a device similar to a device 18 marketed by the manufacturer that has been cleared or approved in the United 19 States – and is also lawfully marketed in a foreign country. 20

103. Thus, even when a device is manufactured to modified specifications
to meet standards in different countries, if these changes do not substantially alter
the performance of the device, then any device events that are MDR reportable
events relating to such modified devices should be reported under the MDR
regulations.

104. Notwithstanding this reporting obligation for events worldwide,
between 2007 and 2010—following premarket approval for its first generation of
silicone-filled breast implants in 2006—internal ALLERGAN documents show

ALLERGAN received 22 worldwide complaints of BIA-ALCL in women

2 implanted with the silicone brand of the breast implants:

2	I to the			Worldwide by Surfa	асе Туре	
3 4 5	Year	Description	Smooth	Textured (Biocell, Microcell, Unknown AGN Textured)	Unknown	Total
	2004	Count of ALCL Complaints by Received Year Sales Volume by Distribution Year	0	0	0 NA	0
6	2005	Count of ALCL Complaints by Received Year	0	0	0	0
7		Sales Volume by Distribution Year Count of ALCL Complaints by Received Year	0	0	NA 0	0
8	2006	Sales Volume by Distribution Year			NA	-
0	2007	Count of ALCL Complaints by Received Year Sales Volume by Distribution Year	1	2	0 NA	3
9	2008	Count of ALCL Complaints by Received Year	0	5	4	9
10		Sales Volume by Distribution Year Count of ALCL Complaints by Received Year	0	3	NA 3	6
	2009	Sales Volume by Distribution Year			NA	
11	2010	Count of ALCL Complaints by Received Year Sales Volume by Distribution Year	1	0	3 NA	4
12	2011	Count of ALCL Complaints by Received Year	0	9	0	9
	2012	Sales Volume by Distribution Year Count of ALCL Complaints by Received Year	1	14	NA 2	17
13	2012	Sales Volume by Distribution Year	4	21	NA	22
14	2013	Count of ALCL Complaints by Received Year Sales Volume by Distribution Year	1	21	0 NA	22
	2014	Count of ALCL Complaints by Received Year	0	18	8 NA	26
15	2015	Sales Volume by Distribution Year Count of ALCL Complaints by Received Year	0	32	4	36
16	Total	Sales Volume by Distribution Year Count of ALCL Complaints by Received Year	4	104	NA 24	132
17	(2004-2015)	Sales Volume by Distribution Year	4	104	NA	132
 18 19 20 21 22 23 24 25 26 27 28 	<i>all</i> . ¹²⁻¹³ Mo ¹² The FD database) <u>https://ww</u> ¹³ The firs of BIA-AI the FDA o <u>https://ww</u>	ALLERGAN unlawfully failed to report these events of BIA-ALCL to the Final. ¹²⁻¹³ Moreover, the internal ALLERGAN data set forth above does not accent action of the FDA's Manufacturer and User Facility Device Experience (MAUDE database) is available online and can be searched to locate MDRs. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm. ¹³ The first instance of ALLERGAN filing an adverse event report for a composed BIA-ALCL in connection with its silicone filled breast implants was receipted by the FDA on May 4, 2011. See https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?m_id=2097844.				count plaint ived by
	-37- COMPLAINT AND DEMAND FOR JURY TRIAL					

1

2

5

7

19

20

21

25

for the untold number of complaints of BIA-ALCL in women implanted with their saline filled brand of BIOCELL Textured Breast Implants.¹⁴

106. Such information, had it been disclosed by ALLERGAN, would have 3 enabled physicians and patients to take proper precautions to determine whether the 4 increased risk of BIA-ALCL should be avoided by electing not to use Allergan's BIOCELL textured implants. Or, the FDA would have recalled the BIOCELL 6 textured implants before Plaintiff ever had them implanted.

107. Also under state law, which does not impose duties or requirements 8 materially different from those imposed by federal law, the manufacturer must 9 timely and appropriately report adverse events concerning the safety of its products. 10 ALLERGAN was under a continuing duty under state law to adequately report 11 injuries and problems with its devices, including the BIOCELL Textured Breast 12 Implants, to the FDA. 13

108. As a result of ALLERGAN's postmarket failure to appropriately report 14 adverse events as required by federal statute and FDA regulations, and as a result of 15 ALLERGAN's postmarket negligence, the defective and unreasonably dangerous 16 17 nature of the product became known only after having been implanted in Plaintiff, and otherwise never would have been implanted in the Plaintiff at all. 18

ALLERGAN violated 21 C.F.R. §§ 803.50 and 803.52 by 2. concealing pertinent adverse event reports by burying them in unscrutinized spreadsheets

22 109. As complaints of BIA-ALCL continued to rise in frequency as outlined in the chart above, rather than complying with the federal statute and 23 regulations on medical device reporting, ALLERGAN began using Alternative 24

26 ¹⁴ Due to safety concerns, from April 1992 until November 2006 silicone gel-filled 27 breast implants were only available in the U.S. to women enrolled in clinical studies, whereas saline-filled breast implants remained in the market during this 28 time via 510(k) approval and, after 2001, premarket approval.

Summary Reports (ASRs) to report of BIA-ALCL events associated with its
 BIOCELL Textured Breast Implants.¹⁵

3

4

5

6

110. ASRs differ from MDRs in that eligible events are aggregated into a single periodic report where only rudimentary information about a particular adverse event is set forth in a line item format within a dense spreadsheet containing thousands of other adverse events.

111. Whereas 21 C.F.R. § 803.52 mandates that a traditional medical device
report must contain dozens of categories and subcategories of information,
including unique product identification, a detailed event description with a
discussion of how the device was involved, and a manufacturer's narrative, an ASR
merely contains generic device and problem coding that was never made available
to the public or physicians before late 2019.¹⁶

112. While the FDA allowed manufacturers to use the ASR reporting 13 system to report *specific* adverse events in lieu of MDR reporting, this was only 14 allowed where compliance with some of the reporting requirements "is not 15 necessary to protect the public health" because such events were "known and 16 well-documented." 60 Fed. Reg. 63,592 (December 11, 1995) (emphasis added). In 17 the case of breast implants, manufacturers like ALLERGAN could only summarize 18 reports of "rupture, leaks, deflation/inflation, wrinkling, capsular contracture, and 19 non-specific complaints."17 20

113. Moreover, under the FDA's October 19, 2000 ASR Guidance for
Industry, the FDA requested that any medical device manufacturer seeking to use
the ASR reporting system affirmatively apply for an exemption, in writing, for
specific device events, as required by 21 C.F.R. § 803.19(b), with the following
information: a statement notifying the FDA of the request to participate in the ASR

²⁶
¹⁵ The ASR program is also referred to by the FDA as Postmarket Spreadsheet
²⁷ Reporting (PSR).

¹⁶ Compare Exhibit A, a single MDR, with Exhibit B, <u>105</u> ASRs.
 ¹⁷ See <u>https://www.accessdata.fda.gov/cdrh_docs/pdf/P990074B.pdf</u>.

program; an explanation why the request is justified; identification of the device
 manufacturer; the product classification codes for the device that will be included in
 the ASR report; and the reporting site registration number, contact person, and
 address of the firm who will be submitting the ASR reports to the FDA.

5

6

7

8

114. ALLERGAN failed to comply with 21 C.F.R. § 803.19(b) and the corresponding ASR Guidance, and used the ASR reporting system to report BIA-ALCL events associated with its BIOCELL Textured Breast Implants despite never being granted an exemption to do so by the FDA.


9 115. The FDA's October 19, 2000 ASR Guidance was clear, device
10 manufacturers could not lawfully use the ASR reporting system under any
11 circumstances for unusual, unique, or even uncommon events. BIA-ALCL, and the
12 symptoms associated therewith, are unequivocally an unusual, unique, or
13 uncommon events—but an event type ALLERGAN was aware of since at least
14 1997 when the first known event appeared in the medical literature with a
15 description of its characteristics.

16 116. Likewise, the FDA was unambiguous in its May 2, 2019 statement
regarding the agency's efforts to protect women's health and help to ensure the
safety of breast implants: "[The ASR] program was established in 1997 to more
efficiently review adverse events for well-established risks but was not allowed for
patient deaths and *unusual, unique or uncommon adverse events, which, in the case of breast implants, included BIA-ALCL.*"

117. On information and belief, hundreds of complaints related to BIAALCL and symptoms associated therewith surfaced from 1997 to 2019, and
ALLERGAN was aware of these events, and that they were unusual, unique, or
uncommon events relating to BIA-ALCL. ALLERGAN—rather than reporting
these events in compliance with the MDR reporting requirements—misused the
ASR reporting system in violation of 21 C.F.R. § 803.19(b); 21 C.F.R. § 803.50; 21
C.F.R. § 820.198(a)(3); 21 U.S.C. 360i; and its duty to report to the FDA.

-40-

1	118. The first identified misuse of the ASR system to report an event of			
2	BIA-ALCL occurred in 2009 when a healthcare professional reported to an			
3	ALLERGAN employee the events of BIA-ALCL and seroma. ¹⁸ However,			
4	following the FDA's decision to end the ASR program due to manufacturer abuse,			
5	the FDA in late 2017 also began to require manufacturers to also submit companion			
6	MDRs so that some information collected through the ASR program would be			
7	visible publicly. As a result, it became known that ALLERGAN has been misusing			
8	the ASR program to report ineligible events since as early as March 1997. ¹⁹			
9	119. In fact, ALLERGAN started late filing hundreds of MDRs related to			
10	BIA-ALCL events it had known about for many years but had buried in the ASR			
11	spreadsheets to belatedly comply with 21 C.F.R. § 803.50; 21 C.F.R. §			
12	820.198(a)(3); and 21 U.S.C. 360i—and also in violation of these statute and			
13	regulations—after the FDA ended the ASR program in late 2017. Two such			
14	examples of the now thousands of MDRs recently filed and available only after			
15	2017 in the FDA's Adverse Event Database clearly demonstrate Allergan's			
16	years/decades-long delay in filing these MDRs:			
17	120. The FDA was not aware, did not consent, and did not grant any			
17 18	120. The FDA was not aware, did not consent, and did not grant any exemption to ALLERGAN to use ASR reporting for BIA-ALCL events.			
18	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search			
18 19	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Catalog Number N-27-MM135-400 Catalog Number N-27-MM135-400			
18 19 20	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Back to Search Results			
18 19 20 21	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the			
18 19 20 21 22	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or			
 18 19 20 21 22 23 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Report Date 01/23/2019			
 18 19 20 21 22 23 24 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Rouniner N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Information 18 medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Image: 18 See https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi_			
 18 19 20 21 22 23 24 25 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Report Date 01/23/2019			
 18 19 20 21 22 23 24 25 26 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014 The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Information in this medwatch was previously reported via 410 psr on 17/jul/2014 The event Of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Image: Report Date 01/23/2019 18 See https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi_id=2842518.			
 18 19 20 21 22 23 24 25 26 27 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/jul/2014. The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Report Date 01/23/2019 ¹⁸ See https://www.acceessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi id=2842518. ¹⁹ See https://www.acceessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi			
 18 19 20 21 22 23 24 25 26 27 	exemption to ALLERGAN to use ASR reporting for BIA-ALCL events. ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results ALLERGAN (COSTA RICA) STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT PROSTHESIS, BREAST, Back to Search Results Catalog Number N-27-MM135-400 Device Problem Adverse Event Without Identified Device or Use Problem Event Type Injury Manufacturer Narrative Information in this medwatch was previously reported via 410 psr on 17/JUI/2014] The event of lymphoma is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event. Further information from the reporter regarding event, product, or Report Date 01/23/2019 18 See https://www.acccessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi_id=2842518. 19 See https://www.acccessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi_id=7326850.			



injuries because either: (a) a recall would have been initiated before Plaintiff's
 implantation date of the subject devices; or (b) the risks would have been well understood and Plaintiff or her physician would have been informed of the risk of
 BIA-ALCL. Instead, the Plaintiff and her physician were both unware of the extent
 of the risk of BIA-ALCL when the subject deivces were implanted causing her
 serious injuries.

125. Accordingly, Plaintiff LINDA HEARNE was injured as a result of
Defendants' postmarket failure to properly submit MDRs as required (by statute
and that FDA's regulations), and as a result of Defendants' postmarket negligence,
ALLERGAN's BIOCELL Textured Breast Implants belatedly became known to be
defective and unreasonably dangerous only *after* having been implanted in Plaintiff.

12 126. As a result of its failure to establish and maintain effective post-market
13 surveillance and reporting to ensure defect-free products, Plaintiff suffered severe
14 injuries.

15 127. Also under state law, which does not impose duties or requirements
16 materially different from those imposed by federal law, the manufacturer must
17 timely and appropriately report adverse events concerning the safety of its products.
18 ALLERGAN was under a continuing duty under state law to adequately report
19 injuries and problems with its devices, including the BIOCELL Textured Breast
20 Implants, to the FDA.

128. As a result of ALLERGAN's postmarket failure to appropriately report
adverse events as required by federal statute and FDA regulations, and as a result of
ALLERGAN's postmarket negligence, the defective and unreasonably dangerous
nature of the product became known only after having been implanted in Plaintiff,
and otherwise never would have been implanted in the Plaintiff at all.

26

3. ALLERGAN failed to investigate and evaluate complaints of BIA-ALCL per 21 C.F.R. §§ 820.198 and 803.18(e) and prepare corresponding medical device reports

129. Pursuant to 21 C.F.R. § 820.198(a), ALLERGAN was required to have a formally designated unit for the purposes of receiving, reviewing and evaluating complaints of adverse events. 21 C.F.R. §§ 803.17, 803.18, and 820.198.

130. The FDA's definition of "complaint" is all encompassing and includes "any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution." 21 C.F.R. § 820.3(b).

11 131. Typically, complaints are prepared and transmitted to the company by
physicians, nurse, hospitals, attorneys, and even the patients themselves on the
comprehensive FDA Form 3500B for voluntary reporters—designed with the intent
of streamlining the manufacturer's reporting by mirroring the information contained
in FDA's Form 3500A for mandatory reporters, like ALLERGAN.

16 132. Upon receipt of a complaint by *any* employee, ALLERGAN was
required to evaluate all available information related to the complaint to determine
whether it represents an MDR reportable event. 21 C.F.R. §§ 820.198(a) and
803.18. Said evaluation must include information in the manufacturer's possession
or that is reasonably available to ALLERGAN, such as information can be obtained
by contacting a user facility (e.g. hospital, surgical center), importer or other initial
reporter related to the adverse event. 21 C.F.R. § 803.50.

133. If the adverse event complaint qualifies for reporting to FDA under 21
C.F.R. Part 803—i.e., the device may have caused or contributed to a death or
serious injury, or malfunctioned—then ALLERGAN was required to conduct an

26

1

2

3

4

5

6

7

8

9


10

1	investigation of the event. 21 C.F.R. §§ 803.3 and 803.50.20 Said investigation must				
2	include a determination (1) whether the device failed to meet specifications; (2)				
3	whether the device was being used for treatment or diagnosis; and (3) the				
4	relationship, if any, of the device to the reported incident or adverse event. 21				
5	C.F.R. § 820.198(d).				
6	134. Accordingly, under these general complaint handling requirements,				
7	ALLERGAN was under the continuing duty to receive, evaluate, and investigate				
8	such events related to BIA-ALCL and make a determination as to the relationship				
9	between the BIOCELL Textured Breast Implants and BIA-ALCL.				
10	135. Notwithstanding ALLERGAN's complaint handling obligations for				
11	adverse events of BIA-ALCL and symptoms associated therewith, on numerous				
12	occasions ALLERGAN ignored complaints of such events.				
13	136. Two such examples of these ignored complaints further demonstrate				
14	ALLERGAN's cavalier and unlawful attitude towards the risks of BIA-ALCL: ²¹				
15	INAMED INAMED SALINE BREAST IMPLANT Back to Search Results				
16	Event Type No Answer Provided Event Description				
10	Alcl case report: this pt had bilateral breast augmentation performed in 2005. She recently developed a seroma that was aspirated and found to have atypical t cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast.				
17					
17	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast.				
17 18	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Search Results				
17 18 19	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells,				
17 18 19 20	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of				
17 18 19 20 21	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into				
17 18 19 20 21 22	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into				
 17 18 19 20 21 22 23 	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Model Number 363LF-300 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. ²⁰ Death or serious injury includes events occurring from: 1) Failure; 2)				
 17 18 19 20 21 22 23 24 	cells. I performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Model Number 363LF-300 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363lf saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. ²⁰ Death or serious injury includes events occurring from: 1) Failure; 2) Malfunction; 3) Improper or inadequate design; 4) Manufacture; 5) Labeling; or 6)				
 17 18 19 20 21 22 23 24 25 	Cells: 1 performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Model Number 3631.F-300 Event Date 12/07/2016 Event Date of the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2016. Ultrasound guided aspiration of serioma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. 20 Death or secrious injury includes events occcurring from: 1) Failure; 2) Malfun				
 17 18 19 20 21 22 23 24 25 26 	Cells: 1 performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363If saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mit showed large loculated right breast fund collection. Aspirated fluid showed cd30+ and aik1 - cells, leading to the diagnosis of aicl. She had bilateral capsulectomise applications and respuelectomic applications on (b)(6) 2017. Pathology did not reveal any extension of the aicl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. ²⁰ Death or serious injury includes events occurring from: 1) Failure; 2) Malfunction; 3) Improper or inadequate design; 4) Manufacture; 5) Labeling; or 6) User error. 21 C.F.R. § 803.3. ²¹ The FDA makes publicly available complaints submitted on the FDA's Form 3500B for voluntary reporters, even when, as here, there is no corresponding				
 17 18 19 20 21 22 23 24 25 26 27 	Cells: 1 performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Model Number 3631.F-300 Event Date 12/07/2016 Event Date of the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2016. Ultrasound guided aspiration of serioma performed on (b)(6) 2016 after ultrasound and mri showed large loculated right breast fluid collection. Aspirated fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. 20 Death or secrious injury includes events occcurring from: 1) Failure; 2) Malfun				
 17 18 19 20 21 22 23 24 25 26 27 	Cells: 1 performed bilateral implant removal and total capsulectomy. Her final pathology revealed aicl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Type Injury Event Description Pt had mcghan 363If saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mit showed large loculated right breast fund collection. Aspirated fluid showed cd30+ and aik1 - cells, leading to the diagnosis of aicl. She had bilateral capsulectomise applications and respuelectomic applications on (b)(6) 2017. Pathology did not reveal any extension of the aicl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. ²⁰ Death or serious injury includes events occurring from: 1) Failure; 2) Malfunction; 3) Improper or inadequate design; 4) Manufacture; 5) Labeling; or 6) User error. 21 C.F.R. § 803.3. ²¹ The FDA makes publicly available complaints submitted on the FDA's Form 3500B for voluntary reporters, even when, as here, there is no corresponding				
 17 18 19 20 21 22 23 24 25 26 27 	Terformed bilateral implant removal and total capsulectomy. Her final pathology revealed alcl of the left breast. MCGHAN MCGHAN 363 LF SALINE FILLED BREAST IMPLANTS Back to Search Results Model Number 363LF-300 Event Date 12/07/2016 Event Date 12/07/2016 Event Date 12/07/2016 Event Date 12/07/2016 Event Description Pt had mcghan 363If saline filled implants placed on (b)(6) 2016. Presented with large right breast seroma on (b)(6) 2016. Ultrasound guided aspiration of seroma performed on (b)(6) 2016 after ultrasound and mr showed large loculated right breast fluid collection. Aspiratef fluid showed cd30+ and alk1 - cells, leading to the diagnosis of alcl. She had bilateral capsulectomies and removal of implants on (b)(6) 2017. Pathology did not reveal any extension of the alcl into the capsular. She is currently being worked up by our oncologists were as well as our geneticists. ²⁰ Death or serious injury includes events occurring from: 1) Failure; 2) Malfunction; 3) Improper or inadequate design; 4) Manufacture; 5) Labeling; or 6) User error. 21 C.F.R. § 803.3. ²¹ The FDA makes publicly available complaints submitted on the FDA's Form 3500B for voluntary reporters, even when, as here, there is no corresponding medical device report submitted by the manufacturer.				

137. Rather than conducting the required investigations in to complaints
 transmitted by concerned physicians and/or patients, ALLERGAN, in violation of
 their general complaint handling requirements, allowed the complaints to fall on
 deaf ears.

- 138. As a result, ALLERGAN never conducted the required evaluation to
 determine whether the complaint qualified for public medical device reporting
 (instances of BIA-ALCL most assuredly qualify), never conducted the required
 investigation to determine the relationship between the event and the device, and
 therefore deprived the FDA or public of vital knowledge necessary to make
 informed decisions about the BIOCELL Textured Breast Implants.
- 11 139. Such information, had it been disclosed by ALLERGAN, would have
 enabled physicians and patients to take proper precautions to determine whether the
 increased risk of BIA-ALCL should be avoided by electing not to use
 14 ALLERGAN'S BIOCELL Textured Breast Implants. Or, the FDA would have
 15 recalled the BIOCELL Textured Breast Implants before Plaintiff ever had them
 16 implanted.
- 140. Also under state law, which does not impose duties or requirements
 materially different from those imposed by federal law, the manufacturer must
 timely and appropriately report adverse events concerning the safety of its products.
 ALLERGAN was under a continuing duty under state law to adequately report
 injuries and problems with its devices, including the BIOCELL Textured Breast
 Implants, to the FDA.
- 141. As a result of ALLERGAN's postmarket failure to appropriately report
 adverse events as required by federal statute and FDA regulations, and as a result of
 ALLERGAN's postmarket negligence, the defective and unreasonably dangerous
 nature of the product became known only after having been implanted in Plaintiff,
 and otherwise never would have been implanted in the Plaintiff at all.
- 28

1	4. ALLERGAN failed to timely submit reports of BIA-ALCL per 21		
2	C.F.R. § 803.50(a) and attempted to transmit such reports years		
3	after first receiving notice of the event		
4	142. As aforementioned, after ALLERGAN's misuse of the ASR program		
5	came to light in late 2017, ALLERGAN belatedly started late filing thousands of		
6	MDRs for a variety adverse event types that were not eligible for ASR reporting		
7	dating back to 1997. Amongst these late reports were hundreds of adverse events		
8	related to BIA-ALCL and symptoms associated therewith that ALLERGAN had		
9	known about for many years, but the existence of which the FDA and the public		
10	had no knowledge of.		
11	143. It was, in part, because of these late MDRs establishing the true extent		
12	of the nexus between BIA-ALCL and the presence of an ALLERGAN's BIOCELL		
13	Textured Breast Implant, that the FDA was equipped with sufficient knowledge to		
14	initiate the July 2019 worldwide recall.		
15	144. Two particularly egregious examples are as follows, revealing		
16	ALLERGAN failed to submit the mandatory MDRs until <i>twelve years</i> and <i>twenty</i> -		
17	<i>nine years</i> after the underlying adverse event, with latter only being reported to the		
18	FDA, and therefore disclosed to the public, as recent as December 11, 2019:		
19	ALLERGAN (COSTA RICA) STYLE 163 SALINE FILLED BREAST IMPLANT PROSTHESIS, BREAST, INFLATABLE, INTERNAL, Back to Search Results		
20	Catalog Number 163-440 Device Problem No Apparent Adverse Event		
21	Event Date 01/01/2007 Event Type Injury Event Description		
22	Health professional reported patient "developed rapid late seroma. Diagnosed with bia-alcl right breast, stage ie, underwent bilateral capsulectomies and implant removal. Received chop, ice, chemotherapy and radiation therapy followed by stem cell transplant postoperatively. Follow up imaging with pet, no		
23	recurrence of disease. Remains healthy. ".		
24	Manufacturer Narrative Unique identifier (udi) #: not applicable. Device labeling addresses: there were no reported events of lymphoma/alcl, for patients in the core study, in the labeling for silicone implants. Potential adverse events that may occur with silicone gel-filled breast implant surgery include; implant rupture, capsular		
25	contracture, reoperation, implant removal, pain, changes in nipple and breast sensation, infection, scarring, asymmetry, wrinkling, implant displacement/migration, implant palpability/visibility, breastfeeding complications, hematoma/seroma, implant extrusion, necrosis, delayed wound healing, breast tissue atrophy/chest wall deformity, calcium deposits, and lymphadenopathy. After breast implant surgery the following may occur and/or persist, with		
26	varying intensity and/or for a varying length of time: hematoma/seroma, implant extrusion, necrosis, delayed wound healing, and breast tissue atrophy/chest wall deformity. Calcium deposits can form in the tissue capsule surrounding the implant with symptoms that may include pain and firmness. Lymphadenopathy has also been reported in some women with implants.		
27	Report Date 08/28/2019		
28			
	-47-		
	COMPLAINT AND DEMAND FOR JURY TRIAL		



recalled the BIOCELL Textured Breast Implants before Plaintiff ever had them
 implanted.

149. Also under state law, which does not impose duties or requirements
materially different from those imposed by federal law, the manufacturer must
timely and appropriately report adverse events concerning the safety of its products.
ALLERGAN was under a continuing duty under state law to adequately report
injuries and problems with its devices, including the BIOCELL Textured Breast
Implants, to the FDA.

9 150. As a result of ALLERGAN's postmarket failure to appropriately
10 report adverse events as required by federal statute and FDA regulations, and as a
11 result of ALLERGAN's postmarket negligence, the defective and unreasonably
12 dangerous nature of the product became known only after having been implanted in
13 Plaintiff, and otherwise never would have been implanted in the Plaintiff at all.

- 14
- 15 16

17


18

5. ALLERGAN failed to provide all information reasonably known to it per 21 C.F.R. § 803.50(b) in its reports of BIA-ALCL but rather simply regurgitated its misleading and deficient labeling

151. A medical device report must contain all the information required by 21 C.F.R. § 803.52 that is known, or reasonably known to the manufacturer.

19 152. Information considered reasonably known includes any information: 1)
20 that can be obtained by contacting a user facility, importer, or other initial reporter;
21 2) that is in the manufacturer's possession; or 3) that can be obtained by analysis,
22 testing or other evaluation of the device. 21 C.F.R. § 803.50(b).

153. Far from providing all information reasonably known it, as part of its
manufacturing narrative in medical device reports concerning BIA-ALCL,
ALLERGAN, more often than not, simply recited its device labeling with the
unsubstantiated and misleading claim that "device labeling addresses" the issue
already, thereby indicating that no further investigatory or remedial action was
needed.



1 158. Such information, had it been disclosed by ALLERGAN, would have
 enabled physicians and patients to take proper precautions to determine whether the
 increased risk of BIA-ALCL should be avoided by electing not to use
 ALLERGAN's BIOCELL Textured Breast Implants. Or, the FDA would have
 recalled the BIOCELL Textured Breast Implants before Plaintiff ever had them
 implanted.

159. Also under state law, which does not impose duties or requirements
materially different from those imposed by federal law, the manufacturer must
timely and appropriately report adverse events concerning the safety of its products.
ALLERGAN was under a continuing duty under state law to adequately report
injuries and problems with its devices, including the BIOCELL Textured Breast
Implants, to the FDA.

13 160. As a result of ALLERGAN's postmarket failure to appropriately
14 report adverse events as required by federal statute and FDA regulations, and as a
15 result of ALLERGAN's postmarket negligence, the defective and unreasonably
16 dangerous nature of the product became known only after having been implanted in
17 Plaintiff, and otherwise never would have been implanted in the Plaintiff at all.

- 18
- 19

20

6. ALLERGAN failed to use the appropriate device problem code for reports of BIA-ALCL instead representing that there was "no apparent adverse event"

161. The FDA receives a significant number of MDRs in any given month
or year. Accordingly, it has implemented and relied upon a problem coding system
to enable FDA officials to conduct trend and risk analysis for a device without the
immediate need to read and review every MDR.

162. There exist four categories of problem codes: 1) Device Problem
Code; 2) Patient Problem Code; 3) Evaluation Results Code; and 4) Evaluation
Conclusion Code. However, only the Device Problem Code on MDRs is made
publicly available on the FDA's MAUDE interface.

1 163. These codes must be provided to the FDA in an adverse event report
 2 pursuant to 21 C.F.R. § 803.52. The codes must represent the manufacturers best
 3 knowledge of the adverse event and a manufacturer is not limited to more than one
 4 code per category for an event. When entering the device problem code,
 5 manufacturers are expected to select the lowest-level (i.e. most detailed) code or
 6 codes that most accurately describe the device failures or problems observed during
 7 the event.

8 164. To the extent the FDA's coding manual does not provide a matching
9 or similar code(s) that would best describe the patient or device problem or the
10 evaluation result and conclusion, a manufacturer has the ability to contact the FDA
11 to assign a new code(s) as applicable.

12 165. However, in violation of 21 C.F.R. § 803.52, rather than providing an
13 accurate device problem code for events of BIA-ALCL, ALLERGAN had a pattern
14 and practice of providing the Device Problem Code No. 3189, meaning "No
15 Apparent Adverse Event."

16 166. As the title suggests, Device Problem Code No. 3189: No Apparent
Adverse Event has a unique meaning to the FDA that "[a] report has been received
but the description provided *does not appear to relate to an adverse event*. This
code allows a report to be recorded for *administration purposes*, even if it *doesn't meet the requirements for adverse event reporting*."²²

21 167. ALLERGAN knew this code was "for FDA use only" because "an
22 event that is not an adverse event is, by definition, not a reportable adverse event."²³

168. ALLERGAN nevertheless utilized this code in their medical device
reporting for events of BIA-ALCL, which had the intended consequence of
excluding these reports from the FDA's trend analysis.

- 26
- 27 28

²³ See <u>https://www.fda.gov/medical-devices/mdr-adverse-event-codes/coding-faqs</u>.

²² See <u>https://www.fda.gov/media/109148/download</u>.

1 169. As a result of ALLERGAN's deceitful coding practices in violation of
 2 21 C.F.R. § 803.52, for years the FDA was deprived of the necessary information to
 3 expeditiously determine the need for regulatory action, such as a recall, without
 4 having to first review and analyze each MDR for the device.

5

6

7

8

9

170. If the FDA's trend analysis had not been undermined by ALLERGAN's reporting practices, the recall would have been initiated before Plaintiff's implantation date of the subject devices; or the risks would have been well-understood and Plaintiff or her physician would have been informed of the risk of BIA-ALCL.

171. Worse yet, this practice of representing events of BIA-ALCL as "no 10 apparent adverse event" was not limited to its domestic reporting practices, but also 11 was ALLERGAN's standard operating procedure internationally. On multiple 12 occasion in its Incident Report Forms to European regulatory authorities, 13 ALLERGAN ranked cases of BIA-ALCL in the fields of "All Other Reportable 14 Incident" and "No Threat of Public Health." As a result, ALLERGAN was 15 reprimanded by French regulatory authorities in May 2015. Nonetheless, 16 17 ALLERGAN continued to use the "No Apparent Adverse Event" code domestically for events of BIA-ALCL. 18

19 172. Such information, had it been disclosed by ALLERGAN, would have
20 enabled physicians and patients to take proper precautions to determine whether the
21 increased risk of BIA-ALCL should be avoided by electing not to use
22 ALLERGAN's BIOCELL textured implants. Or, the FDA would have recalled the
23 BIOCELL textured implants before Plaintiff ever had them implanted.

173. Also under state law, which does not impose duties or requirements
materially different from those imposed by federal law, the manufacturer must
timely and appropriately report adverse events concerning the safety of its products.
ALLERGAN was under a continuing duty under state law to adequately report

injuries and problems with its devices, including the BIOCELL Textured Breast
 Implants, to the FDA.

174. As a result of ALLERGAN's postmarket failure to appropriately report adverse events as required by federal statute and FDA regulations, and as a result of ALLERGAN's postmarket negligence, the defective and unreasonably dangerous nature of the product became known only after having been implanted in Plaintiff, and otherwise never would have been implanted in the Plaintiff at all.

8

7

3

4

5

6

9 10

C. Statement of Facts Relating to Preemption Applicable to Plaintiff's Manufacturing Defect and Negligence Claims

11 175. As noted above, ALLERGAN has received pre-market approval from
12 the FDA for all three generations of BIOCELL Textured Breast Implants. As such,
13 ALLERGAN was under a continuing duty to follow the manufacturing and design
14 specifications mandated by the FDA as part of the PMAs, as well as the general
15 requirements set forth current good manufacturing practices ("CGMPs") provisions
16 of the MDA governing the safety and effectiveness of a PMA medical device. See
17 21 U.S.C. 351; 21 C.F.R. Part 820.

176. Pursuant to the CGMPs regulations, ALLERGAN was obligated to
implement and maintain quality control systems to validate processes and conduct
inspections and testing to ensure the purity and stability of the implants and not
produce adulterated implants, specifically those with excessive particles on the
implant surface at the time of manufacture in violation of 21 U.S.C. 351; 21 C.F.R.
§§ 820.70 and 820.75.

177. Notwithstanding this obligation, ALLERGAN produced, at times,
adulterated BIOCELL Textured Breast Implants that had numerous unwanted
particles and solid fragments of silicone on the implant surface in violation of
manufacturing/ design specifications and CGMP regulations designed to ensure
device quality and patient safety.

1 178. As a result, ALLERGAN failed to properly perform its duties and
 2 failed to implement and maintain quality control systems with respect to the
 3 texturization process for manufacturing its BIOCELL Textured Breast Implants,
 4 even though it was aware that its textured implants regularly contained
 5 contaminants, fragments, particles, and impurities in violation of 21 C.F.R. Part 820
 6 and 21 U.S.C. 351.

179. On information and belief, BIOCELL Textured Breast Implants were
adulterated within the meaning of 21 U.S.C. 351(h) when they were placed in the
stream of commerce by ALLERGAN, in that the methods used in, or the facilities
or controls used for, their manufacture, packing, storage, or installation were not in
conformity with the manufacturing/design specifications and CGMP design
controls enumerated in 21 C.F.R. Part 820 designed to prevent exposing patients to
risks of serious injury or death when the device is used as intended by the surgeon.

180. ALLERGAN violated these regulations, in part, by failing to establish 14 norms and guidelines for biocompatibility, mechanical properties of the shell, 15 modes of sterilization, packaging, and most importantly, surface texturing. As a 16 17 result, ALLERGAN's BIOCELL textured surface—produced through its lost-salt technique—leaves many irregular depressions on the surface of the shell. These 18 pores are—in both diameter and height—significantly larger and much more 19 aggressive than the manufacturing and design specifications mandated by the FDA 20 21 as part of the PMAs, as well as industry standards where nodules are typically a fraction of the size. 22

181. Moreover, this extreme texturing process routinely leads to the
shedding of debris from the implant surface, resulting in significantly greater
quantities of silicone particles in the surrounding capsules than the industry
standard and the product specifications. These shredded particles, over time, give
rise to chronic inflammation which in turn leads to BIA-ALCL.

1 182. It was the duty of ALLERGAN to comply with the PMAs and the
 2 FDA's Quality System Regulations and Current Good Manufacturing Practices. Yet
 3 notwithstanding this duty, ALLERGAN violated the FDCA and the regulations
 4 promulgated pursuant to it.

183. As a consequence, ALLERGAN violated 21 U.S.C. §§ 331, 351(h)
and 21 C.F.R. Part 820 by introducing or delivering for introduction into interstate
commerce a device that was adulterated.

8 184. ALLERGAN violated 21 U.S.C. §§ 331, 351(h) and 21 C.F.R. Part
9 820 by receiving in interstate commerce a device that was adulterated and
10 delivering the device for pay or otherwise.

11 185. ALLERGAN violated 21 U.S.C. §§ 331, 351(h) and 21 C.F.R. Part
12 820 by manufacturing a device that was adulterated.

13 186. ALLERGAN violated 21 C.F.R. § 820.30 by failing to establish and
14 maintain procedures for validating the device design of BIOCELL Textured Breast
15 Implants to ensure that the implants conformed to patients' needs and intended
16 uses, including failing to test production units under actual or simulated use
17 conditions.

187. ALLERGAN violated 21 C.F.R. § 820.50 by failing to establish and 18 maintain procedures to ensure that all purchased or otherwise received product and 19 services conform to specified requirements, including evaluating and selecting 20 21 potential suppliers, contractors, and consultants on the basis of their ability to meet 22 quality requirements; defining the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the 23 evaluation results; and establishing and maintaining records of acceptable suppliers, 24 contractors, and consultants. 25

188. ALLERGAN violated 21 C.F.R. § 820.70(a) by failing to develop,
conduct, control, and monitor production processes to ensure that the BIOCELL
Textured Breast Implants conformed to their specifications, as well as maintaining

process controls to ensure conformance to specifications. This includes, but is not
 limited to, ensuring that the any BIOCELL Textured Breast Implants did not
 exceed the maximum allowable roughness.

4 5 6

7

8

189. ALLERGAN violated 21 C.F.R. § 820.70(h) with respect to its lostsalt process of texturizing by failing to establish and maintain procedures for the use and removal of such manufacturing materials to ensure that the amount of silicone particles embedded on the implant due to this texturizing process is limited to an amount that does not adversely affect the device's quality.

9 190. ALLERGAN violated 21 C.F.R. § 820.90(a) by failing to establish and
10 maintain procedures to control texturized implants that do not conform to
11 specification, including failing to adequately identify, document, evaluate,
12 segregate, and dispose of nonconforming implants.

13 191. ALLERGAN, in violation of 21 C.F.R. § 820.100(a), failed to
14 establish and maintain procedures for implementing corrective and preventive
15 action in order to properly detect recurring quality problems related to the lost-salt
16 process, investigate causes of nonconformities, identifying necessary action to
17 correct and prevent recurrence of nonconforming implants, implementing changes
18 in methods to correct such quality problems, and validating the corrective and
19 preventive action.

192. ALLERGAN violated 21 C.F.R. § 820.22 by failing to establish
procedures for quality audits to determine the effectiveness of the quality system
and to ensure corrective action related to BIOCELL Textured Breast Implants be
taken as necessary.

193. ALLERGAN failed to adequately inspect, test, and validate BIOCELL
Textured Breast Implants after completion of assembly and immediately before
delivery for implantation into consumers, like Plaintiff LINDA HEARNE, to
mitigate the development of bacterial accumulation and other risks which cause
BIA-ALCL, as mandated by 21 C.F.R. § 820.160.

1 194. Upon information and belief, when BIOCELL Textured Breast
 2 Implants were manufactured, ALLERGAN had the technological capability to
 3 manufacture BIOCELL Textured Breast Implants in a reasonably safe manner and
 4 ALLERGAN is held to the level of knowledge of an expert in the field.
 5 ALLERGAN itself had alternative measures to make a safer product, but chose not
 6 to do so in the interests of further its profits.

7 195. Plaintiff LINDA HEARNE was injured as a result of Defendants'
8 postmarket failure to properly implement Good Manufacturing Practices, and as a
9 result of Defendants' postmarket negligence, ALLERGAN's BIOCELL Textured
10 Breast Implants belatedly became known to be defective and unreasonably
11 dangerous only after having been implanted in Plaintiff.

12 196. As a result of its failure to establish and maintain effective post-market
13 quality control standards and good manufacturing practices to ensure defect-free
14 products, Plaintiff suffered severe injuries.

15 197. Also under state law, which does not impose duties or requirements
materially different from those imposed by federal law, the manufacturer must
adequately inspect, test, and validate its product and its components, and monitor
its manufacturing and quality control processes to ensure there are no deviations
from product specifications or regulations that could affect the safety of its
products, such as the BIOCELL Textured Breast Implants.

198. As a result of ALLERGAN's postmarket failure to properly implement
quality control procedures required by federal statute and FDA regulations, as a as a
result of ALLERGAN's postmarket negligence, the products were defective and
unreasonably dangerous when implanted in Plaintiff.

25

26

27

28

-58-

1	D. Statement of Facts Applicable to Plaintiff's Intentional and Negligent
2	Misrepresentation Claims
3	1. ALLERGAN spends <i>years</i> downplaying or dismissing the growing
4	link between BIA-ALCL and the presence of an ALLERGAN
5	BIOCELL Textured Breast Implant
6	199. The first line of BIOCELL Textured Breast Implants was submitted
7	for PMA in November 1999 and approved by the FDA in May 2000 under PMA
8	No. P990074. These previously unregulated implants were then known as McGhan
9	Medical RTV Saline-Filled Breast Implants and utilized ALLERGAN's BIOCELL
10	lost-salt technology.
11	200. But approximately three years prior to that approval, in 1997, the first
12	reported case of ALCL in a patient with a McGhan Medical RTV Saline-Filled
13	Breast Implant (Style 168—one of the recalled implant styles) was published in the
14	journal of Plastic and Reconstructive Surgery. Notably, the location for the
15	lymphoma was encased in the right breast area, evidencing it was related to the
16	implant itself.
17	201. Since then, there have been dozens of medical studies and regulatory
18	alerts examining the progression of BIA-ALCL related knowledge, with one of the
19	earliest studies being commissioned by ALLERGAN.
20	202. In 2003, a team of ALLERGAN consultants, advisors, and research
21	coordinators initiated a 14-year prospective clinical study concerning 42,035
22	BIOCELL Textured Breast Implants and their link to BIA-ALCL.
23	203. Importantly, the ALLERGAN Study was not designed to determine
24	whether there exists a link between BIOCELL Textured Breast Implants to BIA-
25	ALCL—that fact was already presumed by the ALLERGAN Study. Instead, the
26	ALLERGAN Study was seeking to determine if employing certain sterilization
27	techniques at the time of implantation of a BIOCELL Textured Breast Implants
28	

would mitigate the risk of developing BIA-ALCL in light of the disease's nexus to 1 bacterial accumulation.²⁴ 2

3

204. Also in 2003, a case report and review of the literature in The Archives of Pathology and Laboratory Medicine, *Anaplastic Large Cell Lymphoma Arising* 4 in a Silicone Breast Implant Capsule: A Case Report and Review of the Literature, 5 that a silicone gel-filled implant placed in the left breast in 1991 resulted in BIA-6 7 ALCL in the left breast diagnosed in March 2000. Notably, pathology of the left breast capsule showed refractile material consistent with silicone particles in close 8 proximity to the tumor cells. 9

205. In 2007, ALLERGAN received at least three complaints of BIA-10 ALCL in women implanted with silicone filled breast implants, two of which were 11 confirmed to have been implanted with ALLERGAN textured breast implants. The 12 number of complaints received by ALLERGAN of BIA-ALCL in women 13 implanted with saline filled breast implants for the same time period is still 14 unknown. 15

206. BIA-ALCL first garnered attention after 2008, when a study described 16 four patients with a CD30-positive T-cell lymphoproliferative disorder surrounding 17 breast implants. 18

207. In November 2008, the Journal of the American Medical Association 19 published a study by a group of Dutch researchers that had identified 11 patients 20 with breast implants and reported BIA-ALCL of the breast diagnosed between 1990 21 22 and 2006. The study found a positive association between breast implants and the development of ALCL, with an odds ratio of 18:1—meaning that patients with 23 implants were 18 times more likely to develop BIA-ALCL than patients without 24 25 breast implants.

- 26
- 27 28

²⁴ Macrotextured Breast Implants with Defined Steps to Minimize Bacterial Contamination around the Device: Experience in 42,000 Implants. Plastic and Reconstructive Surgery. 140. 427-431.

208. In 2008, ALLERGAN received at least nine complaints of BIA-ALCL 1 2 in women implanted with silicone filled breast implants, five of which were confirmed to have been implanted ALLERGAN textured breast implants. The 3 number of complaints received by ALLERGAN of BIA-ALCL in women 4 implanted with saline filled breast implants for the same time period is still 5 unknown. 6

209. On November 24, 2008, a healthcare professional reports to an 7 ALLERGAN employee the events of BIA-ALCL and seroma. Rather than reporting 8 the event to the FDA in an MDR, ALLERGAN buries the complaint in the 2009 9 Alternative Summary Reporting spreadsheet. 10

11

210. In 2009, ALLERGAN received at least six complaints of BIA-ALCL in women implanted with silicone filled breast implants, three of which were 12 confirmed to have been implanted with ALLERGAN textured breast implants. The 13 number of complaints received by ALLERGAN of BIA-ALCL in women 14 implanted with saline filled breast implants for the same time period is still 15 unknown. 16

211. In 2010, ALLERGAN received at least four complaints of BIA-ALCL 17 in women implanted with silicone filled breast implants. The number of complaints 18 of BIA-ALCL in women implanted with saline filled breast implants for the same 19 time period is still unknown. 20

212. On May 25, 2010, ALLERGAN files an MDR for the first time 21 22 following an event of BIA-ALCL associated with one of their saline filled breast implants which resulted in the death of the patient. The entirety of ALLERGAN's 23 manufacturer narrative for this death was redacted by ALLERGAN as "(b)(4)" 24 meaning the information constitutes "trade secrets and commercial or financial 25 information." 26

213. In January 2011, the FDA issued a report titled "Anaplastic Large Cell 27 Lymphoma (ALCL) In Women with Breast Implants." The report stated that "in a 28

thorough review of scientific literature published from January 1997 through May
 2010, the FDA identified 34 unique cases of ALCL." The FDA concluded, *"The FDA believes that there is a possible association between breast implants and ALCL.* "The FDA further noted that, "ALCL has been found *more frequently in association with breast implants having a textured outer shell rather than a smooth outer shell.*"

7 214. Despite the FDA's January 2011 Report, a spokeswoman for
8 ALLERGAN, whose products were linked to the cases, downplayed the concerns in
9 an emailed statement: "A woman is more likely to be struck by lightning than get
10 this condition," said Caroline Van Hove. "Patients' safety is Allergan's absolute
11 first priority and we continue all efforts to collect and analyze further information
12 about the very rare occurrence of ALCL in patients with breast implants."

13 215. In 2011, ALLERGAN received at least nine complaints of BIA-ALCL
14 in women implanted with silicone filled breast implants, all nine of which were
15 confirmed to have been implanted with ALLERGAN textured breast implants. The
16 number of complaints received by ALLERGAN of BIA-ALCL in women
17 implanted with saline filled breast implants for the same time period is still
18 unknown.

19 216. On March 16, 2011, the FDA received the first MDR from
20 ALLERGAN for an event of BIA-ALCL associated with one of their silicone filled
21 breast implants where the operative notes described a "moderate brown liquid" in
22 the implant capsule.

217. In 2012, the first cases of BIA-ALCL in women with breast implants
began to be reported in Australia. This prompted ALLERGAN to publish a second
study, in May 2012, estimating the incidence of developing BIA-ALCL at 1.46 for
every 100,000 breast implants.

27 218. The ALLERGAN-sponsored study was described as using "crude
28 figures," but nevertheless was used by the company to downplay the risk to patients

and effectively served to silence debate among academics and regulators on the
 emerging issue.

219. In 2012, ALLERGAN received at least seventeen complaints of BIAALCL in women implanted with silicone filled breast implants, fourteen of which
were confirmed to have been implanted with ALLERGAN textured breast implants.
The number of complaints received by ALLERGAN of BIA-ALCL in women
implanted with saline filled breast implants for the same time period is still
unknown.

9 220. In 2013, ALLERGAN received at least twenty-two complaints of BIA10 ALCL in women implanted with silicone filled breast implants, twenty-one of
11 which were confirmed to have been implanted with ALLERGAN textured breast
12 implants. The number of complaints received by ALLERGAN of BIA-ALCL in
13 women implanted with saline filled breast implants for the same time period is still
14 unknown.

15 221. On December 8, 2014, a major analysis of the breast implant and BIAALCL connection was published, which identified 173 cases of BIA-ALCL. The
authors reviewed 37 articles in the world literature reporting on 79 patients and
collected another 94 unreported cases. The study confirmed that there are no known
pure smooth implant cases. Additionally, the study determined that out of 170
breast implants, in 61 cases the manufacturer was unknown yet in 97 cases (or
56%) the implants were BIOCELL Textured Breast Implants.

22 222. In 2014, ALLERGAN received at least twenty-six complaints of BIA23 ALCL in women implanted with silicone filled breast implants, eighteen of which
24 were confirmed to have been implanted with ALLERGAN textured breast implants.
25 The number of complaints received by ALLERGAN of BIA-ALCL in women
26 implanted with saline filled breast implants for the same time period is still
27 unknown.

223. Also, in March 2015, the French National Cancer Institute (Agence
 Nationale de Sécurité du Médicament, "ANSM") announced, "There is a *clearly established link* between the occurrence of this disease and the presence of a breast
 implant."

5 224. In 2015, ALLERGAN received at least thirty-six complaints of BIA6 ALCL in women implanted with silicone filled breast implants, thirty-two of which
7 were confirmed to have been implanted with ALLERGAN textured breast implants.
8 The number of complaints received by ALLERGAN of BIA-ALCL in women
9 implanted with saline filled breast implants for the same time period is still
10 unknown.

11 225. In 2016, more information continued to come out addressing the link
12 between breast implants and BIA-ALCL as regulatory agencies around the world
13 began making more definitive and stronger statements alerting of the link. For
14 example, in May 19, 2016, the World Health Organization ("WHO") issued a
15 guidance definitively linking breast implants to ALCL and officially named the
16 disease "breast implant associated ALCL."

17 226. In July 2016, the ANSM released an update stating that, based upon 29
18 cases of ALCL reported, and due to the predominance of textured cases, it was
19 calling for all implant manufacturers selling in France to submit clear data for
20 textured implants within the year or their respective devices would be restricted
21 from sale.

22 227. In November 2016, Australia's Therapeutic Goods Administration
23 ("TGA") convened an expert advisory panel to discuss the association between
24 breast implants and BIA-ALCL and to provide ongoing advice. In December 2016,
25 the TGA issued a report about BIA-ALCL which indicated a substantially higher
26 risk associated with textured versus smooth implants. Furthermore, the TGA27 reported incidence rate was in the range of 1:1,000-10,000 for patients with
28 textured implants

228. On December 28, 2016, ALLERGAN sponsored a third study 1 2 purported to examine the incidence of capsular contracture, malposition and late seroma in patients that received the ALLERGAN's Style 410 breast implant. The 3 study found that out of the 17,656 patients, four developed ALCL. This would in 4 fact suggest an incidence rate, at the time of the study, of close to 1:4,000 for the 5 now recalled Style 410 implants. Nevertheless, the study found that the incidence of 6 capsular contracture, implant malposition and late seroma were low enough to 7 conclude that, "[t]hese data reaffirm the safety of the Natrelle 410 breast implant." 8

229. In April 2017, researchers from the M.D. Anderson Cancer Center in 9 Houston performed a literature review on the etiology of ALCL and confirmed that 10 "textured implants are commonly implicated in the development" of BIA-ALCL. 11 12 Additionally, the study pulled information from the adverse events reports from the FDA's MAUDE database to determine the distribution of BIA-ALCL by 13 manufacturer. The data showed that out of the US cases reported to the FDA 14 MAUDE database, 184 (or 80.3%) of the ALCL cases reported were 15 **ALLERGAN's BIOCELL Textured Breast Implants.** 16

17 230. In March 2018, the FDA issued an update which reported a total of
18 414 received reports of BIA-ALCL- up from 359 a year earlier. The report stated
19 that the lifetime risk for BIA-ALCL is between 1 in 3,817 and 1 in 30,000 women
20 with textured breast implants.

21 231. In August 2018, the FDA reported that of the 272 cases of BIA-ALCL
22 for which the implant surface was known, approximately 89% were textured. The
23 FDA further noted that the real number of cases and size of the risk was not known,
24 because there was a lack of information about how many women in the United
25 States and worldwide had received implants.

26 232. On August 3, 2018, researchers from the M.D. Anderson Cancer
27 Center reported that the risk of BIA-ALCL for patients implanted with
28 ALLERGAN's BIOCELL Textured Breast Implants after a decade of could be as

great as 1 in 2,200. This estimate was extrapolated from ALLERGAN's own two
 studies of its Style 410 BIOCELL Textured Breast Implants, published on
 December 28, 2016, as discussed above. At the time the study was published, four
 women out of 17,656 had developed BIA-ALCL. By August 2018, eight women of
 the 17,656 had developed BIA-ALCL.

6 233. As discussed further below, and despite these mounting issues,
7 ALLERGAN continued to downplay and dismiss the prevalence of BIA-ALCL in
8 connection with its Textured Breast Implants, and continued to market, sell,
9 distribute, and push those implants onto consumers, including Plaintiff, around the
10 world.

11

2.

12 13

As early as 2010, when ALLERGAN would publicly address BIA-ALCL in its adverse event reports, they were riddled with halftruths and misrepresentations

234. Despite actually possessing exclusive knowledge about the risks of 14 BIA-ALCL particular to the BIOCELL Textured Breast Implants, for decades 15 ALLERGAN failed to publish, disseminate, or otherwise communicate, in any 16 17 form, and by any means, the true risk of BIA-ALCL. ALLERGAN omitted material information about the disease not just to the FDA, but also to the medical and 18 scientific community, device user facilities, and consumers like Plaintiff as part of a 19 deliberate and intentional effort to induce such persons and entities to rely on the 20 omissions and to allow the BIOCELL Textured Breast Implants to be in and remain 21 22 in the marketplace for purchase. Through its omissions alone, ALLERGAN actively conspired to and did conceal the risks of BIA-ALCL associated with the 23 **BIOCELL** Textured Breast Implants. 24

25 235. Moreover, despite the growing number of complaints, studies and
26 concerns regarding the link between textured implants and BIA-ALCL,
27 ALLERGAN continued to make false and misleading statements regarding BIA28 ALCL and the presence of an ALLERGAN BIOCELL Textured Breast Implant.

1			
1	236.	In particular, ALLERGAN's false and incomplete statements surfaced	
2	in its hundreds of adverse event reports prepared following events of BIA-ALCL.		
3	237. As described above, the reporting requirements under 21 C.F.R. §		
4	803.52 are stringent and a medical device manufacturer "must include" in the		
5	medical device reports information "reasonably known" to it, including:		
6	(1)	an identification of the adverse event or product problem;	
7	(2)	a description of the event or problem, including a discussion of how	
8		the device was involved, nature of the problem, patient followup or	
9		required treatment, and any environmental conditions that may have	
10		influenced the event;	
11	(3)	a summary of the evaluation of the device, or an explanation of why an	
12		evaluation was not perform;	
13	(4)	evaluation codes (including event codes, method of evaluation, result,	
14		and conclusion codes);	
15	(5)	whether remedial action was taken and the type of action; and	
16	(6)	an explanation of why any required information was not provided in	
17		the MDR and the steps taken to obtain this information.	
18	238.	A medical device report must contain such information if it is known,	
19	or reasonably known to the manufacturer. 21 C.F.R. § 803.50(b). Information		
20	considered	reasonably known includes any information: 1) that can be obtained by	
21	contacting a user facility, importer, or other initial reporter; 2) that is in the		
22	manufacturer's possession; or 3) that can be obtained by analysis, testing or other		
23	evaluation of	of the device. 21 C.F.R. § 803.50(b)(i)-(iii).	
24	239.	Thus, ALLERGAN had a duty on all matters related to events of BIA-	
25	ALCL associated with their BIOCELL Textured Breast Implants to report in a		
26	manner that avoided omitting any material fact required by 21 C.F.R. § 803.52 that		
27	was known or reasonably known to it.		
28			

240. However, as part of a scheme designed to downplay the risks of
 BIOCELL Textured Breast Implants in the MDRs and to induce the FDA, the
 medical and scientific community, device user facilities, and consumers like
 Plaintiff into believing that there was no unique risks of BIA-ALCL associated with
 their BIOCELL Textured Breast Implants in order to sell more implants,
 ALLERGAN willfully concealed and failed to disclose all required information
 reasonably known to it in the adverse event reports.

8 241. In hundreds of adverse event reports following complaints from health
9 care facilities, hospitals, physicians, nurse, and the patients themselves pertaining to
10 events related to BIA-ALCL, rather than providing an honest account of the
11 relationship between the device and the occurrence of BIA-ALCL in the report
12 based on the knowledge in its possession as required by the applicable regulations,
13 ALLERGAN for years provided incomplete information and/or simply quoted its
14 device labeling.

15 242. For example, in an MDR dated November 1, 2010, ALLERGAN
16 stated in its narrative for an event of BIA-ALCL:

17

18

19

20

21

22

23

26

27

28

Device labeling addresses [. . .] *There were no reported events of cancer including lymphoma for patients in the a95/r95 study included in the labeling for saline breast implants* [. . .] "If unusual symptoms occur after surgery, such as fever or noticeable swelling or redness in one breast, you should contact your surgeon immediately. ". (Ratified by ALLERGAN Director of Global Product Support, Lee Champion, 71 South Los Carneros, Goleta, California 93117.)

24 243. Again, in a medical device report regarding BIA-ALCL dated March
25, 2011, ALLERGAN stated:

Device labeling addresses: there were no reported event of lymphoma/alcl for pts in the (b)(4) study included in the labeling for saline breast implants. "if unusual symptoms occur after surgery, such

as fever or noticeable swelling or redness in one breast, you should 1 contact your surgeon immediately. ". (Ratified by ALLERGAN 2 Director of Global Product Support, Lee Champion, 71 South Los 3 Carneros, Goleta, California 93117.) 4 244. On July 5, 2012: 5 Device labeling reviewed: there were no reported events of 6 lymphoma/alcl, for pts in the core study, in the labeling for silicone 7 implants. (Ratified by ALLERGAN Director of Global Product 8 Surveillance, Karen Herrera, 71 South Los Carneros, Goleta, 9 California 93117.) 10 245. On December 27, 2012: 11 Allergan product labeling for saline implants: there were no reported 12 events of lymphoma/alcl, for patients in the (b)(4) study, as well as the 13 (b)(4) study ((b)(4) study) included in the labeling for saline breast 14 implants. (Ratified by ALLERGAN Director of Global Product 15 Surveillance, Karen Herrera, 71 South Los Carneros, Goleta, 16 California 93117.) 17 246. On May 2, 2014: 18 Device labeling reviewed: there were no reported events of 19 20 lymphoma/alcl observed in the care study, in the labeling for silicone implants. There were no reported events of lymphoma/alcl observed in 21 22 the (b)(4) study included in the labeling for saline breast implants. (Ratified by ALLERGAN Director of Global Product Surveillance, 23 Karen Herrera, 71 South Los Carneros, Goleta, California 93117.) 24 247. On March 5, 2015: 25 Potential adverse events that may occur with saline-filled breast 26 implant surgery include: [. . .] Published studies indicate that breast 27 cancer is no more common in women with implants than those without 28

implants. A large, long-term follow-up found no significant increases in the risk rates for a wide variety of cancers, including stomach cancer, leukemia, and lymphoma. (Ratified by ALLERGAN Quality Assurance Associate, Krista Alvarado, 301 W Howard Lane #100, Austin, Texas 78753.)

248. On June 25, 2015:

Based on the info reported to fda and found in medical literature, *a possible association has been identified between breast implants and the rare development of anaplastic large cell lymphoma (alcl)*, a type of non-hodgkins' lymphoma. Women with breast implants may have a very small but increased risk of developing alcl in the fluid or scar capsule adjacent to the implant. Alcl has been reported globally in pts *with an implant history that includes allergan's and other mfrs' breast implants*. (Ratified by ALLERGAN Quality Assurance Associate, Krista Alvarado, 301 W Howard Lane #100, Austin, Texas 78753.)

17 249. On March 31, 2016:

Device labeling addresses: "lymphoma, including anaplastic large tcell lymphoma (alcl) - information from medical literature has suggested a possible association, *without evidence of causation*, between breast implants and the very rare occurrence of alcl in the breast. *The disease is exceptionally rare*, may present as a late occurring peri-prosthetic seroma, and *occurs in women with and without breast implants*. (Ratified by ALLERGAN Director of Global Product Surveillance, Suzanne Wojcik, 301 W Howard Lane #100, Austin, Texas 78753.)

250. On July 26, 2017:

28

27

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

18

19

20

21

22

23

24

25

Device labeling: alcl has been reported globally in patients with an *implant history that includes allergan's and other manufacturers' breast implants*. You should consider the possibility of alcl when you have a patient with late onset, persistent peri-implant seroma. (Ratified by ALLERGAN Director of Global Product Surveillance, Suzanne Wojcik, 301 W Howard Lane #100, Austin, Texas 78753.)

251. Finally, after a decade of disinformation but nonetheless still inadequately, on February 24, 2018, ALLERGAN begins to state:

Based on information reported to global regulatory agencies and found in medical literature, an association has been identified between breast implants and the development of anaplastic large cell lymphoma (alcl), a type of non-hodgkin's lymphoma. Women with breast implants may have a very small but increased risk of developing breast implant associated alcl (bia-alcl) in the fluid or scar capsule adjacent to the implant, with documented potential for local, regional, and distant spread of the cancer with mortality reported in rare cases. Bia-alcl has been reported globally in patients with an implant history that includes allergan's and other manufacturers' breast *implants with various surface properties, styles, and shapes.* Most of the cases in the literature reports describe a history of the use of (Ratified by ALLERGAN Director of Global textured implants. Product Surveillance, Suzanne Wojcik, 301 W Howard Lane #100, Austin, Texas 78753.)

24 252. In light of ALLERGAN's sophisticated knowledge of the nature of the
25 BIA-ALCL and its relationship to its BIOCELL Textured Breast Implant—which
26 was exclusively known internally within ALLERGAN as early as 2003—each of
27 the above- representations by ALLERGAN, and the hundreds more like them, were

28

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

false, incomplete, and misleading in the context in which they were made, and were 1 known to be so when made. 2

253. The principle fraudulent omission in these adverse events was the failure to acknowledge that BIA-ALCL is exclusively found in textured implants 4 and that ALLERGAN's BIOCELL Textured Breast Implants are, by far, associated with more cases than any other type of textured implant.

254. These representations created the false impression that the full extent 7 of BIA-ALCL's relationship with the textured breast implants was already a known 8 and disclosed risk, and further that ALLERGAN's breast implants were no more 9 likely to be found in individuals suffering from BIA-ALCL than other companies' 10 products. 11

255. Plaintiff, by and through the FDA, medical and scientific community, 12 and her device user facility, justifiably relied upon ALLERGAN's misleading and 13 incomplete representations concerning BIA-ALCL and its nexus to the BIOCELL 14 Textured Breast Implants. 15

256. Had Plaintiff known the true facts relating to BIA-ALCL and its nexus 16 to the BIOCELL Textured Breast Implants, Plaintiff would not have elected to be 17 implanted with BIOCELL Textured Breast Implants, but rather would have chosen 18 a different style of implant or forwent implantation altogether. 19

20

3

5

6

21

22

23

E. **Statement of Facts Relating to Causation Applicable to All Counts**

1. The connection between ALLERGAN's failure to report and **Plaintiff's injuries**

257. As a result of Allergan's failure to appropriately file MDRs to the FDA 24 as required by 21 U.S.C. 360i and 21 C.F.R. § 803.50—its BIOCELL textured 25 implants were misbranded postmarket. 26

258. Plaintiff further alleges that Defendants failed to take reasonable 27 postmarket corrective action to warn, either directly or through an appropriate 28

channel, physicians who had implanted its devices, and patients in whom they had
 been implanted, of the risks of BIA-ALCL.

259. Such warnings, had they been given, would have caused physicians
and patients, like Plaintiff, to take proper precautions to determine whether the
substantially increased risk of BIA-ALCL should be avoided by electing not to use
ALLERGAN'S BIOCELL Textured Breast Implants. Or, the FDA would have
recalled the BIOCELL Textured Breast Implants before Plaintiff ever had them
implanted.

9 260. Allergan was or should have been aware that its BIOCELL Textured
10 Breast Implants carried a much greater risk of BIA-ALCL than other textured
11 implant products, or compared to smooth implant products—yet Allergan failed to
12 give effective postmarket notice to the FDA, physicians, and patients to put them
13 on adequate notice of the problem, and failed to inform them of how to avoid that
14 risk.

15 261. Also under state law, which does not impose duties or requirements
16 materially different from those imposed by federal law, the manufacturer must
17 timely and appropriately report adverse events concerning the safety of its products.
18 ALLERGAN was under a continuing duty under state law to adequately report
19 injuries and problems with its devices, including the BIOCELL Textured Breast
20 Implants, to the FDA.

262. As a result of Allergan's postmarket failure to properly implement
procedures required by federal statute and FDA regulations, and as a result of
ALLERGAN's postmarket negligence, the defective and unreasonably dangerous
nature of the product became known only after having been implanted in Plaintiff,
and otherwise would have never would have been implanted in the Plaintiff at all.

26

2 3

4

5

6

1

2.

The connection between ALLERGAN's failure to implement quality control systems and Plaintiff's injuries

263. As a result of ALLERGAN's failure to establish such quality systems as required by 21 C.F.R. Part 820—its BIOCELL Textured Implants were adulterated within the meaning of 21 U.S.C. 351(h) when they were placed in the stream of commerce by ALLERGAN.

7 264. Plaintiff further alleges that Defendants failed to take reasonable
8 postmarket corrective and preventive action in order to properly detect recurring
9 quality problems related to the lost-salt process and implement changes in methods
10 to correct such quality problems.

265. Such corrective and preventive action, had they been implemented,
 would have prevented Plaintiff from being exposed to an aggressive, potentially
 fatal form of lymphoma. Or, the FDA would have recalled the BIOCELL Textured
 Breast Implants before Plaintiff ever had them implanted.

15 266. Also under state law, which does not impose duties or requirements
16 materially different from those imposed by federal law, the manufacturer must
17 adequately inspect, test, and validate its product and its components, and monitor
18 its manufacturing and quality control processes to ensure there are no deviations
19 from product specifications or regulations that could affect the safety of its
20 products, such as the BIOCELL Textured Breast Implants.

267. As a result of ALLERGAN's postmarket failure to properly implement
quality control procedures required by federal statute and FDA regulations, as a as a
result of ALLERGAN's postmarket negligence, the products were defective and
unreasonably dangerous when implanted in Plaintiff.

25 268. ALLERGAN was or should have been aware that its BIOCELL
26 Textured Breast Implants carried a much greater risk of BIA-ALCL than other
27 textured implant products, or compared to smooth implant products—yet
28 ALLERGAN failed to implement effective postmarket action to mitigate or

eliminate the risk of BIA-ALCL, and failed to inform physicians and patients of how that risk could be avoided.

3 4

5

6

7

1

2

3. The connection between ALLERGAN's misrepresentations and Plaintiff's injuries

269. As discussed above, adverse event reports published in the FDA's MAUDE database represent a public communication by a manufacturer about a device's performance and its relationship to a particular adverse health event.

8 270. These adverse event reports are routinely reviewed by the FDA to
9 monitor device performance, detect potential device-related safety issues, and
10 contribute to benefit-risk assessments of these products.

11 271. Moreover, such reports are relied upon by the medical and scientific
12 community, including cancer researchers as described above, as a valuable source
13 of information in learning about the genesis of an adverse health event and any
14 adverse health trends associated with a medical device.

15 272. Device user facilities, including hospitals, outpatient facilities, nursing
homes and surgical facilities, routinely analyze the medical device reports when
determining the risks of selling one particular medical device over another, or one
brand over another. For example, with respect to breast implants, a device user
facility relies upon the information contained in the medical device reports when
deciding whether to sell smooth or textured implants, or ALLERGAN's brand over
a competitor.

22 273. To the extent the medical device reports contain false, inaccurate, or
23 incomplete information, the FDA is deprived of vital information needed to detect
24 potential device-related safety issues and disseminate public alerts about particular
25 device problem and/or its association to a particular disease.

26 274. Likewise, the medical and scientific community is deprived of the
27 information needed to educate their patients and obtain informed consent about the
28 risks in choosing a particular device.

275. Further, device user facilities are unable to make informed decisions 1 2 about the risks of offering for purchase a particular medical device over others on the market. 3

276. ALLERGAN fraudulently omitted in its adverse event reports 4 associated with the BIOCELL Textured Breast Implants that BIA-ALCL is 5 exclusively found in textured implants and that ALLERGAN's BIOCELL Textured 6 Breast Implants are associated with more cases than any other type of textured implant. 8

277. These incomplete representations created the false impression that the 9 full extent of BIA-ALCL's relationship with the textured breast implants was 10 already a known and disclosed, and further that ALLERGAN's breast implants were 11 no more likely to be found in individuals suffering from BIA-ALCL than other 12 13 companies' products.

278. Moreover, ALLERGAN had actual knowledge of the material facts as 14 alleged herein regarding the risks of BIA-ALCL and the presence of an 15 ALLERGAN BIOCELL Textured Breast Implant. However, for decades, 16 17 ALLERGAN outright failed or refused disclose such facts in any form, whether it by through their adverse event reports or any other communication, although such 18 facts were readily available.

279. Plaintiff, by and through the FDA, medical and scientific community, 20 21 and her device user facility, justifiably relied upon ALLERGAN's omissions, and 22 misleading and incomplete representations concerning BIA-ALCL and its nexus to the BIOCELL Textured Breast Implants. 23

280. As a result of Allergan's failure to disclose all of the known risks

associated with BIOCELL Textured Breast Implants and BIA-ALCL, including in

misrepresentations and omissions, the defective and unreasonably dangerous nature

the adverse event reports, and as a result of ALLERGAN's fraudulent

24

19

7

25 26

27

of the product became known only after having been implanted in Plaintiff, and 1 otherwise would have never would have been implanted in the Plaintiff at all. 2 3 FIRST CAUSE OF ACTION 4 (Strict Product Liability-Failure to Warn) 5 **Against All Defendants** 6 281. Plaintiff incorporates by reference all preceding paragraphs of this 7 Complaint as if fully set forth herein and further alleges as follows: 8 282. At all times pertinent hereto, Defendants directly or through their 9 agents, apparent agents, servants or employees designed, manufactured, tested, 10 marketed, and commercially distributed its BIOCELL Textured Breast Implants to 11 12 clinics, hospitals and plastic surgeons, who ultimately operated and implanted them in consumers' bodies. 13 283. Defendants directly or through their agents, apparent agents, servants 14 or employees designed, manufactured, tested, marketed, and commercially 15 distributed the BIOCELL Textured Breast Implants implanted into Plaintiff's body. 16 17 284. The BIOCELL Textured Breast Implants that were implanted into Plaintiff were defective and unreasonably dangerous when they left the possession 18 of the Defendants as a result of inadequate warnings, including: 19 failing to provide adequate warnings, information, or both, to alert 20 (a) consumers and their prescribing physicians that the BIOCELL 21 22 Textured Breast Implants posed an unreasonably high risk of causing **BIA-ALCL** once implanted; 23 (b) failing to properly market the BIOCELL Textured Breast Implants in 24 light of the BIOCELL Textured Breast Implants' cancerous 25 propensities; 26 27 28 -77-COMPLAINT AND DEMAND FOR JURY TRIAL

1	(c)	failing to ensure the performance of the BIOCELL Textured Breast	
2	Implants conformed to the representations made by Defendants		
3	concerning the risk of BIA-ALCL; and		
4	(d)	representing that the BIOCELL Textured Breast Implants were	
5		suitable for their intended use; and	
6	(e)	failing to handle the BIOCELL Textured Breast Implants in a manner	
7		that conformed to applicable federal laws and regulations.	
8	285.	Such warnings, if given, would have caused such physicians and	
9	patients to b	be informed when selecting the appropriate breast implant and would	
10	have enabled patients, including Plaintiff, to avoid the risks of developing BIA-		
11	ALCL.		
12	286.	Rather, Defendants continued to disseminate product labeling that was	
13	inadequate and defective despite having received postmarket information regarding		
14	BIA-ALCL after the FDA approved such labeling—information Defendants failed		
15	to report to FDA in violation of the MDA and the regulations promulgated		
16	thereunder.		
17	287.	At all relevant times, under federal law and regulation, Defendants	
18	were under	a continuing duty to monitor the product after premarket approval, and	
19	to discover and report to the FDA any complaints about the product's performance		
20	and any adverse health consequences or AERs of which it became aware and that		
21	are, or may be, attributable to the product.		
22	288.	Defendants failed to submit appropriate medical device reports to	
23	inform the FDA of the danger of developing BIA-ALCL in connection with the		
24	BIOCELL Textured Breast Implants, as required by 21 C.F.R. § 803.50, even		
25	though they	should have been aware of such adverse incidents and were actually	
26	aware of su	ch incidents, including at least 22 events of BIA-ALCL Defendants had	
27	received be	tween 2007-2010.	
28			

1	289.	Instead, ALLERGAN exploited the FDA's non-public ASR program	
2	to bury evidence of its BIOCELL Textured Breast Implants causing BIA-ALCL. As		
3	a result, Defendants failed to fulfill its duty to report to the FDA per 21 C.F.R. §		
4	803.50, and warn physicians or patients—including Plaintiff—implanted with		
5	ALLERGA	N's BIOCELL Textured Breast Implants of the dangers of BIA-ALCL.	
6	290.	In addition to its unlawful use of the ASR program, ALLERGAN	
7	failed to:		
8	(a)	Investigate and evaluate complaints of BIA-ALCL per 21 C.F.R. §§	
9		820.198 and 803.18(e) and prepare corresponding medical device	
10		reports;	
11	(b)	Timely submit reports of BIA-ALCL per 21 C.F.R. § 803.50(a) and	
12		instead attempted to transmit such reports years after first receiving	
13		notice of the event;	
14	(c)	Provide all information reasonably known to it per 21 C.F.R. §	
15		803.50(b) in its reports of BIA-ALCL but rather simply regurgitated its	
16		misleading and deficient labeling; and	
17	(d)	Use the appropriate device problem code for reports of BIA-ALCL per	
18		21 C.F.R. § 803.52 but instead represented there was "no apparent	
19		adverse event."	
20	291.	Defendants, as developers and manufacturers of the BIOCELL	
21	Textured Breast Implants, are held to the level of knowledge of experts in the field		
22	of that type of breast implant, and had a duty to warn its consumers and prescribing		
23	physicians of the dangers associated with the implants and failed to do so.		
24	292.	At the time Plaintiff's physician implanted the BIOCELL Textured	
25	Breast Impla	ants, her physician did not have substantially the same knowledge as the	
26	Defendants about the unreasonably high risks of causing BIA-ALCL because the		
27	Defendants	failed to provide adequate warnings of those risks.	
28			

293. As the direct and proximate result of Defendants' failure to warn of the 1 2 defective condition of the BIOCELL Textured Breast Implants, the Plaintiff was implanted with BIOCELL Textured Breast Implants and suffered, or will suffer, 3 painful removal procedures to mitigate the risk of developing BIA-ALCL, as well 4 as any treatment, therapy, recovery, and expense associated with the removal of the 5 BIOCELL Textured Breast Implants, the potential for the development of BIA-6 7 ALCL, and any condition or symptoms associated with BIA-ALCL or the prevention of that issue. 8

9 294. As a further proximate result of Defendants' failure to warn of the
10 defective condition of the BIOCELL Textured Breast Implants, Plaintiff suffered
11 debilitating physical pain and mental suffering, was/will be required to undergo
12 additional surgeries and other procedures, incurred substantial hospital, medical,
13 nursing and pharmaceutical expenses therefrom; suffered emotional distress,
14 anxiety, depression and disability; loss of earnings; and loss of quality of life, and
15 all of these injuries are permanent and continuing.

295. The FDCA contains an express preemption provision, 21 U.S.C.
360k(a), which as relevant, states: "no State or political subdivision of a State may
establish or continue in effect with respect to a device intended for human use any
requirement-- (1) which is different from, or in addition to, any requirement
applicable under this Act to the device, and (2) which relates to the safety or
effectiveness of the device or to any other matter included in a requirement
applicable to the device under this Act."

23 296. This cause of action is based on the Defendants' postmarket violations24 of federal safety statutes and regulations.

25 297. Moreover, Plaintiff does not bring the underlying action as an implied
26 statutory cause of action but rather she is pursuing parallel state common law
27 claims based upon Defendants' violations of the applicable federal statutes and
28 regulations.

298. Plaintiff's strict product liability for failing to warn claim is, thus, not 1 2 preempted by Section 360k(a), because the violations alleged are all based on federal statutory and regulatory standards which includes no "requirement which is 3 different from, or in addition to, any requirement applicable under" the FDCA and 4 regulations promulgated thereunder. As such, the claims set forth in this cause of 5 action contain requirements that are parallel to the FDCA and regulations 6 promulgated thereunder. 7 8 **SECOND CAUSE OF ACTION** 9 (Strict Product Liability-Manufacturing Defect) 10 **Against All Defendants** 11 299. Plaintiff incorporates by reference all preceding paragraphs of this 12 Complaint as if fully set forth herein and further alleges as follows: 13 300. At all times material hereto, Defendants, directly or indirectly, created, 14 manufactured, assembled, designed, sterilized, tested, packaged, labeled, marketed, 15 promoted, advertised, sold and/or distributed into the stream of commerce 16 17 **BIOCELL** Textured Breast Implants, including the BIOCELL Textured Breast Implants implanted into Plaintiff. 18 301. Defendants directly or through their agents, apparent agents, servants 19 or employees designed, manufactured, tested, marketed, and commercially 20 distributed the BIOCELL Textured Breast Implants implanted into Plaintiff's body. 21 22 302. The BIOCELL Textured Breast Implants that were implanted into Plaintiff were defective and unreasonably dangerous when they left the possession 23 of the Defendants in one or more of the following ways: 24 (a) manufacturing and selling BIOCELL Textured Breast Implants that 25 differ from the specifications set forth in the PMA, its Supplements, 26 the Conditions of Approval, and/or other federal regulations; 27 28

1	(b)	manufacturing and selling BIOCELL Textured Breast Implants with	
2		nonconforming materials and uncertified components, inconsistent	
3	with the specifications set forth in the PMA, its Supplements, the		
4		Conditions of Approval, or other federal regulations;	
5	(c)	manufacturing, distributing, and selling BIOCELL Textured Breast	
6		Implants knowing, or while capable of knowing, that they created an	
7		unreasonably high risk of causing BIA-ALCL when implanted into	
8		patients, including the Plaintiff;	
9	(d)	incorporating components into BIOCELL Textured Breast Implants	
10		that could not stand up to normal usage;	
11	(e)	failing or refusing to properly meet the applicable standard of care by	
12		not complying with applicable federal laws and regulations in	
13		manufacturing, marketing, selling, and distributing the BIOCELL	
14		Textured Breast Implants;	
15	(f)	failing or refusing to exercise reasonable care in its inspecting and	
16		testing of the BIOCELL Textured Breast Implants both before and	
17		after they were placed on the market which, if properly performed,	
18		would have shown that the device caused serious side effects,	
19		including BIA-ALCL;	
20	(g)	failing or refusing to exercise reasonable care in its manufacturing and	
21		quality control processes; and	
22	(h)	placing an unsafe and defective breast implant into the stream of	
23		commerce.	
24	303.	Such measures, if implemented, would have mitigated or eliminated	
25	the risk pos	ed by silicone particles shredding from the BIOCELL Textured Breast	
26	Implants an	d would have enabled patients, including Plaintiff, to avoid the risks of	
27	developing	BIA-ALCL.	
28			

304. At all relevant times, under federal law and regulation, Defendants 1 were also required to comply with the FDA's Quality System Regulations and 2 Current Good Manufacturing Practices under 21 C.F.R. Part 820, which, among 3 other things, requires that each manufacturer put procedures in place to test 4 products for compliance with product specifications, document and check 5 compliance with product specifications before products are accepted for sale and 6 7 use, and identify and control all products that fail to conform with product specifications. 8

9 305. It was the duty of the Defendants to comply with the FDCA, and the
10 regulations promulgated pursuant to it. Yet, notwithstanding this duty, Defendants
11 violated the FDCA and regulations in one or more of the following ways:

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

(a)	introducing or delivering for introduction into interstate commerce a
	device that was adulterated due to differences from the specifications
	set forth in the PMA, its Supplements (21 U.S.C. §§ 331, 351(h) and
	21 C.F.R. Part 820);

- (b) receiving in interstate commerce a device that was adulterated and delivering the device for pay or otherwise (21 U.S.C. §§ 331, 351(h) and 21 C.F.R. Part 820);
- (c) manufacturing a device that was adulterated (21 U.S.C. §§ 331, 351(h) and 21 C.F.R. Part 820);

(d) failing to establish and maintain procedures for validating the device design of BIOCELL Textured Breast Implants to ensure that the implants conformed to patients' needs and intended uses, including failing to test production units under actual or simulated use conditions (21 C.F.R. §820.30);

(e) failing to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluating and selecting potential

1		suppliers, contractors, and consultants on the basis of their ability to		
2	meet quality requirements; defining the type and extent of control to			
3	exercised over the product, services, suppliers, contractors, and			
4	consultants, based on the evaluation results; and establishing and			
5	maintaining records of acceptable suppliers, contractors, and			
6	consultants (21 C.F.R. §820.50);			
7	(f)	failing to develop, conduct, control, and monitor production processes		
8		to ensure that the BIOCELL Textured Breast Implants conformed to		
9		their specifications, as well as maintaining process controls to ensure		
10		conformance to specifications. This includes, but is not limited to,		
11		ensuring that the any BIOCELL Textured Breast Implants did not		
12		exceed the maximum allowable roughness (21 C.F.R. §820.70(a));		
13	(g)	failing to establish and maintain procedures with respect to its lost-salt		
14		process of texturizing for the use and removal of such manufacturing		
15		materials to ensure that the amount of silicone particles embedded on		
16		the implant due to this texturizing process is limited to an amount that		
17		does not adversely affect the device's quality (21 C.F.R. §820.70(h));		
18	(h)	failing to establish and maintain procedures to control texturized		
19		implants that do not conform to specification, including failing to		
20		adequately identify, document, evaluate, segregate, and dispose of		
21		nonconforming implants (21 C.F.R. §820.90(a));		
22	(i)	failing to establish and maintain procedures for implementing		
23		corrective and preventive action in order to properly detect recurring		
24		quality problems related to the lost-salt process, investigate causes of		
25		nonconformities, identifying necessary action to correct and prevent		
26		recurrence of nonconforming implants, implementing changes in		
27		methods to correct such quality problems, and validating the corrective		
28		and preventive action (21 C.F.R. §820.100(a));		

1	(j)	failing to establish procedures for quality audits to determine the		
2	effectiveness of the quality system and to ensure corrective action			
3	related to BIOCELL Textured Breast Implants be taken as necessary			
4	(21 C.F.R. §820.22);			
5	(k) failing to adequately inspect, test, and validate BIOCELL Textured			
6	Breast Implants after completion of assembly and immediately before			
7	delivery for implantation into consumers, like Plaintiff, to mitigate th			
8		development of bacterial accumulation and other risks which cause		
9		BIA-ALCL (21 C.F.R. §820.160); and		
10	(1)	failing to monitor, receive, review, and evaluate and/or investigate		
11		complaints received from breast implant patients and their physicians,		
12		failing to timely identifying any problems with one of its devices and,		
13		failing to take appropriate corrective actions to ensure consumer safety		
14		(21 C.F.R. § 820.198).		
15	306.	Because Defendants failed to follow specifications, regulations, and		
16	required go	od manufacturing practices, Plaintiff's BIOCELL Textured Breast		
17	Implants we	ere at a heightened risk of causing the development of BIA-ALCL.		
18	307.	Upon information and belief, Defendants had the technological		
19	capability to manufacture BIOCELL Textured Breast Implants in a reasonably safe			
20	manner and	is held to the level of knowledge of an expert in the field.		
21	308.	As the direct and proximate result of Defendant's acts and omissions		
22	concerning the BIOCELL Textured Breast Implants, the Plaintiff was implanted			
23	with BIOCI	ELL Textured Breast Implants and suffered, or will suffer, painful		
24	removal procedures to mitigate the risk of developing BIA-ALCL, as well as any			
25	treatment, t	herapy, recovery, and expense associated with the removal of the		
26	BIOCELL	Textured Breast Implants, the potential for the development of BIA-		
27	ALCL, and	any condition or symptoms associated with BIA-ALCL or the		
28	prevention	of that issue.		

309. As a further proximate result of Defendant's acts and omissions
 concerning the BIOCELL Textured Breast Implants, Plaintiff suffered debilitating
 physical pain and mental suffering, was/will be required to undergo additional
 surgeries and other procedures, incurred substantial hospital, medical, nursing and
 pharmaceutical expenses therefrom; suffered emotional distress, anxiety, depression
 and disability; loss of earnings; and loss of quality of life, and all of these injuries
 are permanent and continuing.

310. The FDCA contains an express preemption provision, 21 U.S.C.
360k(a), which as relevant, states: "no State or political subdivision of a State may
establish or continue in effect with respect to a device intended for human use any
requirement-- (1) which is different from, or in addition to, any requirement
applicable under this Act to the device, and (2) which relates to the safety or
effectiveness of the device or to any other matter included in a requirement
applicable to the device under this Act."

15 311. This cause of action is based on the Defendants' postmarket violations16 of federal safety statutes and regulations.

312. Moreover, Plaintiff does not bring the underlying action as an implied
statutory cause of action but rather she is pursuing parallel state common law
claims based upon Defendants' violations of the applicable federal statutes and
regulations.

313. Plaintiff's manufacturing defect claim is, thus, not preempted by
Section 360k(a), because the violations alleged are all based on federal statutory
and regulatory standards which includes no "requirement which is different from,
or in addition to, any requirement applicable under" the FDCA and regulations
promulgated thereunder. As such, the claims set forth in this cause of action contain
requirements that are parallel to the FDCA and regulations promulgated thereunder.

1	THIRD CAUSE OF ACTION		
2	(Negligence)		
3	Against All Defendants		
4	314. Plaintiff incorporates by reference all preceding paragraphs of this		
5	Complaint as if fully set forth herein and further alleges as follows:		
6	315. At all times pertinent hereto, Defendants directly or through their		
7	agents, apparent agents, servants or employees designed, manufactured, tested,		
8	marketed, and commercially distributed their BIOCELL Textured Breast Implants		
9	to clinics, hospitals and plastic surgeons, who ultimately operated and implanted		
10	them in consumers' bodies.		
11	316. Defendants directly or through their agents, apparent agents, servants		
12	or employees designed, manufactured, tested, marketed, and commercially		
13	distributed the BIOCELL Textured Breast Implants implanted into Plaintiff's body.		
14	317. Defendants owed Plaintiff, and the public, a duty to use reasonable		
15	care in testing and inspecting their BIOCELL Textured Breast Implants, in		
16	designing the BIOCELL Textured Breast Implants placed into Plaintiff and in		
17	manufacturing and marketing those BIOCELL Textured Breast Implants.		
18	318. The BIOCELL Textured Breast Implants that were implanted into		
19	Plaintiff were defective and unreasonably dangerous when they left the possession		
20	of the Defendants in that the BIOCELL Textured Breast Implants did not conform		
21	to applicable federal laws and regulations.		
22	319. At all relevant times, Defendants violated the FDA's Quality System		
23	Regulations and Current Good Manufacturing Practices under 21 C.F.R. Part 820,		
24	because ALLERGAN produced adulterated BIOCELL Textured Breast Implants		
25	that had numerous unwanted particles and solid fragments of silicone on the		
26	implant surface in violation of CGMP regulations designed to ensure device quality		
27	and patient safety.		
28			

320. Such measures, if implemented, would have caused mitigated or
 eliminated the risk posed by silicone particles shredding from the BIOCELL
 Textured Breast Implants and would have enabled patients, including Plaintiff, to
 avoid the risks of developing BIA-ALCL.

5

6

7

8

9

10

321. Defendants also violated the above described post-market reporting requirements under 21 C.F.R. Part 803 for the BIOCELL Textured Breast Implants, by virtue of their abuses of the FDA's ASR Program and other reporting violations. As a result, Defendants negligently failed to adequately warn of the dangers of BIA-ALCL, and test its product before Plaintiff was implanted with ALLERGAN's BIOCELL Textured Breast Implants.

322. Such warnings, if given, would have enabled the FDA, as well as the
medical and scientific community, to ensure physicians and patients were
adequately informed when selecting the appropriate breast implant and would have
enabled patients, including Plaintiff, to avoid being exposed to BIA-ALCL.

323. Plaintiff was implanted with BIOCELL Textured Breast Implants
without adequate warning and with manufacturing defects, in violation of the
general regulatory requirements, resulting in serious injury to Plaintiff. The injuries
Plaintiff suffered are expected to have resulted from such defects. Plaintiff and her
physician were unaware that the BIOCELL Textured Breast Implants were
defective at the time of implant and thereafter.

21 324. As the direct and proximate result of Defendant's negligent acts and 22 omissions concerning the BIOCELL Textured Breast Implants, the Plaintiff was implanted with BIOCELL Textured Breast Implants and suffered, or will suffer, 23 painful removal procedures to mitigate the risk of developing BIA-ALCL, as well 24 as any treatment, therapy, recovery, and expense associated with the removal of the 25 BIOCELL Textured Breast Implants, the potential for the development of BIA-26 27 ALCL, and any condition or symptoms associated with BIA-ALCL or the prevention of that issue. 28

325. As a further proximate result of Defendant's negligent acts and
 omissions concerning the BIOCELL Textured Breast Implants, Plaintiff suffered
 debilitating physical pain and mental suffering, was/will be required to undergo
 additional surgeries and other procedures, incurred substantial hospital, medical,
 nursing and pharmaceutical expenses therefrom; suffered emotional distress,
 anxiety, depression and disability; loss of earnings; and loss of quality of life, and
 all of these injuries are permanent and continuing.

326. The FDCA contains an express preemption provision, 21 U.S.C. §
360k(a), which as relevant, states: "no State or political subdivision of a State may
establish or continue in effect with respect to a device intended for human use any
requirement-- (1) which is different from, or in addition to, any requirement
applicable under this Act to the device, and (2) which relates to the safety or
effectiveness of the device or to any other matter included in a requirement
applicable to the device under this Act."

15 327. This cause of action is based on the Defendants' postmarket violations16 of federal safety statutes and regulations.

328. Moreover, Plaintiff does not bring the underlying action as an implied
statutory cause of action but rather she is pursuing parallel state common law
claims based upon Defendants' violations of the applicable federal statutes and
regulations.

329. Under California's doctrine of negligence per se, failure to exercise due 21 care is presumed from a violation of a "statute, ordinance, or regulation of a public 22 entity." Cal. Evid. Code, § 669(a)(1). By its terms, this doctrine applies to the law 23 of any public entity, not just California public entities. See, e.g., *DiRosa v. Showa* 24 Denko K.K. (1996) 44 Cal.App.4th 799, 808. Thus, under California law, a money 25 damages remedy exists for negligent violation of the FDCA and regulations 26 promulgated thereunder which proximately cause injuries, and there is no need for 27 California's Legislature to act in order to create such a remedy. 28

1	330. Plaintiff's negligence claim is, thus, not preempted by Section 360k(a),		
2	because the violations alleged are all based on federal statutory and regulatory		
3	standards which includes no "requirement which is different from, or in addition to,		
4	any requirement applicable under" the FDCA and regulations promulgated		
5	thereunder. As such, the claims set forth in this cause of action contain		
6	requirements that are parallel to the FDCA and regulations promulgated thereunder.		
7			
8	FOURTH CAUSE OF ACTION		
9	(Fraud – Intentional Misrepresentation and Concealment)		
10	Against All Defendants		
11	331. Plaintiff incorporates by reference all preceding paragraphs of this		
12	Complaint as if fully set forth herein and further alleges as follows:		
13	332. Each Defendant actively participated in, agreed to, aided and abetted,		
14	conspired in, and/or furthered a fraudulent scheme, as set forth herein, which		
15	conduct constitutes fraud and deceit.		
16	333. Defendants superior knowledge and expertise, their relationship of		
17	trust and confidence with doctors and the public, their specific knowledge regarding		
18	the risks and dangers of BIA-ALCL and their international dissemination of		
19	promotional and marketing information about BIOCELL Textured Breast Implants		
20	for the purpose of maximizing its sale, each give rise to the affirmative duty to		
21	meaningfully disclose important material facts concerning the safety of the		
22	BIOCELL Textured Breast Implants, specifically regarding the risks of developing		
23	BIA-ALCL.		
24	334. Defendants omitted material information to the FDA, the medical and		
25	scientific community, device user facilities, and consumers like Plaintiff as part of a		
26	deliberate and intentional effort to induce such persons and entities to rely on the		
27	omissions and to allow the BIOCELL Textured Breast Implants to be in and remain		
28	in the marketplace for purchase. Through their omissions, Defendants actively		

3

4

5

6

conspired to and did conceal the risks of BIA-ALCL associated with the BIOCELL
 Textured Breast Implants.

335. Defendants omitted material information regarding the risks of BIA-ALCL and the presence of an ALLERGAN BIOCELL Textured Breast Implants with intent to defraud the FDA, the medical and scientific community, device user facilities, and consumers like Plaintiff.

7 336. Defendants intentionally failed to disclose material facts to the FDA,
8 the medical and scientific community, device user facilities, and consumers like
9 Plaintiff that they had a duty to disclose, including the risks of BIA-ALCL
10 associated with the BIOCELL Textured Breast Implants. Each Defendant was
11 aware of and/or approved the material omissions by or on behalf of Defendants.

337. Moreover, Defendants made representations about BIA-ALCL but did
not disclose facts which materially qualified the facts disclosed, which rendered
their disclosure likely to mislead. The true facts about BIA-ALCL and the presence
of an ALLERGAN BIOCELL Textured Breast Implants were known to
Defendants, and Defendants knew they were not known to or reasonably
discoverable by Plaintiff.

338. Defendants knew that their half-truths, concealment and failure to 18 disclose to Plaintiff, by and through the FDA, medical and scientific community, 19 20 and her device user facility, all information reasonably available to them related to the nexus between BIA-ALCL and their BIOCELL Textured Breast Implants, 21 22 would mislead Plaintiff by creating the false impression that the full extent of BIA-ALCL's relationship with the BIOCELL Textured Breast Implants was already a 23 known and disclosed by ALLERGAN, and further that ALLERGAN's breast 24 implants were no more likely to be found in individuals suffering from BIA-ALCL 25 than other companies' products. Defendants also knew that if Plaintiff became 26 aware of the cancerous propensities associated the BIOCELL Textured Breast 27 Implants, Plaintiff would not agree to purchase said implants. 28

339. Nevertheless, in willful disregard of Plaintiff's rights and the duties
 owed to Plaintiff by Defendants, and each of them, concealed and failed to disclose
 to Plaintiff all information reasonably available to them related to the nexus
 between BIA-ALCL and their BIOCELL Textured Breast Implants with the express
 purpose of inducing Plaintiff against her own interest to purchase their cancerous
 breast implants.

7 340. Likewise, Defendants had a statutory and regulatory duty on all
8 matters related to adverse events of BIA-ALCL associated with their BIOCELL
9 Textured Breast Implants to report in a manner that avoided making any written or
10 oral communication containing an untrue statement or omitting any material fact
11 necessary to make statements made, in light of the circumstances under which they
12 were made, not misleading.

341. However, as part of their scheme designed to downplay the risks of
BIOCELL Textured Breast Implants in the medical device reports and to induce the
FDA, the medical and scientific community, device user facilities, and consumers
like Plaintiff into believing that there was no unique risks of BIA-ALCL associated
with their BIOCELL Textured Breast Implants in order to sell more implants,
Defendants willfully concealed and failed to disclose all information reasonably
known to it in the MDRs.

342. The principle fraudulent omission in these MDRs was the failure to
acknowledge that BIA-ALCL is exclusively found in textured implants and that
ALLERGAN's BIOCELL Textured Breast Implants are associated with more cases
than any other type of textured implant–by far.

343. Moreover, Defendants omitted, suppressed, and concealed material
facts concerning the dangers and risks of injuries associated with BIOCELL
Textured Breast Implants and BIA-ALCL, including by exploiting the FDA's nonpublic ASR program to hide evidence of it BIOCELL Textured Breast Implants
causing BIA-ALCL. Specifically, Defendants deliberately failed to file medical

device reports associated with BIA-ALCL events despite its obligations under 21 1 U.S.C. 360 and 21 C.F.R. § 803.50—and deliberately and willfully concealed the 2 increased risk of BIA-ALCL associated with its BIOCELL Textured Breast 3 Implants when it either did not reports these events in any form to the FDA, or 4 unlawfully used the ASR reporting system to report these complaints. 5

344. Defendants intended the FDA, the medical and scientific community, and device user facilities, and patients to rely on the Defendants' important material representations and concealment regarding the safety of the BIOCELL Textured Breast Implants and their link to BIA-ALCL.

345. Plaintiff, by and through the FDA, medical and scientific community, 10 and her device user facility, did in fact rely on and were induced by Defendants' 11 misrepresentations, omissions, or active concealment of the dangers of BIOCELL 12 Textured Breast Implants and the link to BIA-ALCL. 13

14

15

16

6

7

8

9

346. Plaintiff, her physician, her device user facility, and the medical and scientific community did not know that the representations made by the Defendants were false and were justified in relying upon Defendants' representations.

347. As the direct and proximate result of Defendant's fraudulent 17 misrepresentations and intentional concealment of facts concerning the BIOCELL 18 Textured Breast Implants, upon which Plaintiff reasonably relied, she was 19 implanted with BIOCELL Textured Breast Implants and suffered, or will suffer, 20 painful removal procedures to mitigate the risk of developing BIA-ALCL, as well 21 22 as any treatment, therapy, recovery, and expense associated with the removal of the BIOCELL Textured Breast Implants, the potential for the development of BIA-23 ALCL, and any condition or symptoms associated with BIA-ALCL or the 24 prevention of that issue. 25

26

348. As a further proximate result of Defendant's fraudulent misrepresentations and intentional concealment of facts concerning the BIOCELL 27 Textured Breast Implants, Plaintiff suffered debilitating physical pain and mental 28

suffering, was/will be required to undergo additional surgeries and other 1 procedures, incurred substantial hospital, medical, nursing and pharmaceutical 2 expenses therefrom; suffered emotional distress, anxiety, depression and disability; 3 loss of earnings; and loss of quality of life, and all of these injuries are permanent 4 and continuing. 5 349. Defendants' fraudulent misrepresentations evidenced their callous, 6 reckless, willful, and depraved indifference to the health, safety, and welfare of 7 consumers, including Plaintiff, as well as their goal to place company profits over 8 the safety of hundreds of thousands of consumers, subjecting Defendants to 9 punitive and exemplary damages according to the reprehensibility of their conduct 10 and based on the wealth of said Defendants. 11

FIFTH CAUSE OF ACTION

(Negligent Misrepresentation and Concealment) Against All Defendants

16 350. Plaintiff incorporates by reference all preceding paragraphs of this17 Complaint as if fully set forth herein and further alleges as follows:

12

13

14

15

18 351. Each Defendant negligently participated in, agreed to, aided and
abetted, conspired in, and/or furthered a fraudulent scheme, as set forth herein,
which conduct constitutes negligent misrepresentation and concealment.

352. Defendants superior knowledge and expertise, their relationship of 21 22 trust and confidence with doctors and the public, their specific knowledge regarding the risks and dangers of BIA-ALCL and their international dissemination of 23 promotional and marketing information about BIOCELL Textured Breast Implants 24 for the purpose of maximizing its sale, each give rise to the affirmative duty to 25 meaningfully disclose important material facts concerning the safety of the 26 BIOCELL Textured Breast Implants, specifically regarding the risks of developing 27 **BIA-ALCL**. 28

353. Defendants negligently omitted material information to the FDA, the
 medical and scientific community, device user facilities, and consumers like
 Plaintiff which induced such persons and entities to rely on the omissions and to
 allow the BIOCELL Textured Breast Implants to be in and remain in the
 marketplace for purchase. Through their negligent omissions, Defendants concealed
 the risks of BIA-ALCL associated with the BIOCELL Textured Breast Implants.

7 354. Defendants negligently omitted material information regarding the
8 risks of BIA-ALCL and the presence of an ALLERGAN BIOCELL Textured
9 Breast Implants to the FDA, the medical and scientific community, device user
10 facilities, and consumers like Plaintiff.

355. Defendants negligently failed to disclose material facts to the FDA, the
medical and scientific community, device user facilities, and consumers like
Plaintiff that they had a duty to disclose, including the risks of BIA-ALCL
associated with the BIOCELL Textured Breast Implants. Each Defendant was
aware of and/or approved the material omissions by or on behalf of Defendants.

356. Moreover, Defendants made representations about BIA-ALCL but did
not disclose facts which materially qualified the facts disclosed, which rendered
their disclosure likely to mislead. The true facts about BIA-ALCL and the presence
of an ALLERGAN BIOCELL Textured Breast Implants were known to
Defendants, and Defendants knew they were not known to or reasonably
discoverable by Plaintiff.

357. Defendants knew that their half-truths, concealment and negligent
failure to disclose to Plaintiff, by and through the FDA, medical and scientific
community, and her device user facility, all information reasonably available to
them related to the nexus between BIA-ALCL and their BIOCELL Textured Breast
Implants, would mislead Plaintiff by creating the false impression that the full
extent of BIA-ALCL's relationship with the BIOCELL Textured Breast Implants
was already a known and disclosed by ALLERGAN, and further that

-95-

ALLERGAN's breast implants were no more likely to be found in individuals
 suffering from BIA-ALCL than other companies' products. Defendants also knew
 that if Plaintiff became aware of the cancerous propensities associated the
 BIOCELL Textured Breast Implants, Plaintiff would not agree to purchase said
 implants.

6 358. Nevertheless, in a negligent disregard of Plaintiff's rights and the
7 duties owed to Plaintiff by Defendants, and each of them, concealed and
8 negligently failed to disclose to Plaintiff all information reasonably available to
9 them related to the nexus between BIA-ALCL and their BIOCELL Textured Breast
10 Implants, thereby inducing Plaintiff against her own interest to purchase their
11 cancerous breast implants.

12 359. Likewise, Defendants had a statutory and regulatory duty on all
13 matters related to adverse events of BIA-ALCL associated with their BIOCELL
14 Textured Breast Implants to report in a manner that avoided making any written or
15 oral communication containing an untrue statement or omitting any material fact
16 necessary to make statements made, in light of the circumstances under which they
17 were made, not misleading.

360. However, Defendants negligently downplayed the risks of BIOCELL
Textured Breast Implants in the medical device reports, thereby inducing the FDA,
the medical and scientific community, device user facilities, and consumers like
Plaintiff into believing that there were no unique risks of BIA-ALCL associated
with their BIOCELL Textured Breast Implants. As a result, ALLERGAN
negligently concealed and failed to disclose all information reasonably known to it
in the MDRs.

361. The principle fraudulent omission in these MDRs was the failure to
acknowledge that BIA-ALCL is exclusively found in textured implants and that
ALLERGAN'S BIOCELL Textured Breast Implants are associated with more cases
than any other type of textured implant–by far.

362. Moreover, Defendants negligently omitted, suppressed, and concealed 1 2 material facts concerning the dangers and risks of injuries associated with BIOCELL Textured Breast Implants and BIA-ALCL, including by exploiting the 3 FDA's non-public ASR program to hide evidence of it BIOCELL Textured Breast 4 Implants causing BIA-ALCL. Specifically, Defendants negligently failed to file 5 medical device reports associated with BIA-ALCL events despite its obligations 6 under 21 U.S.C. 360 and 21 C.F.R. § 803.50—and negligently concealed the 7 increased risk of BIA-ALCL associated with its BIOCELL Textured Breast 8 Implants when it either did not reports these events in any form to the FDA, or 9 unlawfully used the ASR reporting system. 10

363. Defendants intended the FDA, the medical and scientific community,
and device user facilities, and patients to rely on the Defendants' important material
representations regarding the safety of the BIOCELL Textured Breast Implants and
its link to BIA-ALCL.

15 364. Plaintiff, by and through the FDA, the medical and scientific
16 community, and her device user facility, did in fact rely on and were induced by
17 Defendants' negligent misrepresentations, omissions, or concealment of the dangers
18 of BIOCELL Textured Breast Implants and the link to BIA-ALCL.

19 365. Plaintiff, her physician, her device user facility, and the medical and
20 scientific community did not know that the representations made by the Defendants
21 were false and were justified in relying upon Defendants' representations.

366. As the direct and proximate result of Defendant's negligent
misrepresentations and concealment of facts concerning the BIOCELL Textured
Breast Implants, upon which Plaintiff reasonably relied, she was implanted with
BIOCELL Textured Breast Implants and suffered, or will suffer, painful removal
procedures to mitigate the risk of developing BIA-ALCL, as well as any treatment,
therapy, recovery, and expense associated with the removal of the BIOCELL

Textured Breast Implants, the potential for the development of BIA-ALCL, and any 1 2 condition or symptoms associated with BIA-ALCL or the prevention of that issue. 367. As a further proximate result of Defendant's negligent 3 misrepresentations and concealment of facts concerning the BIOCELL Textured 4 Breast Implants, Plaintiff suffered debilitating physical pain and mental suffering, 5 was/will be required to undergo additional surgeries and other procedures, incurred 6 7 substantial hospital, medical, nursing and pharmaceutical expenses therefrom; suffered emotional distress, anxiety, depression and disability; loss of earnings; and 8 loss of quality of life, and all of these injuries are permanent and continuing. 9 10 **PUNITIVE DAMAGE ALLEGATIONS** 11 (Brought by Plaintiff Against Defendants) 12 368. Plaintiff incorporates by reference all preceding paragraphs of this 13 Complaint as if fully set forth herein and further alleges as follows: 14 369. The acts, conduct, and omissions of Defendants, and each of them, as 15 alleged throughout this Complaint were willful and malicious and were done with a 16 conscious disregard for the rights of Plaintiff as a user of Defendants' BIOCELL 17 Textured Breast Implants and for the primary purpose of increasing Defendants' 18 profits from the sale and distribution of BIOCELL Textured Breast Implants. 19 Defendants' outrageous and unconscionable conduct warrants an award of 20 exemplary and punitive damages against each Defendant in an amount appropriate 21 22 to punish and make an example of each Defendant.

370. Prior to the manufacturing, sale, and distribution of BIOCELL
Textured Breast Implants, Defendants and each of them knew that said implants
were in a defective condition as previously described herein and knew that those
who were implanted with BIOCELL Textured Breast Implants would be at a
heightened risk of developing BIA-ALCL, and would therefore experience and did
experience severe physical, mental and emotional injuries. Further, Defendants and

each of them through their officers, directors, managers, and agents, had knowledge
 that the BIOCELL Textured Breast Implants presented a substantial and
 unreasonable risk of harm due to BIA-ALCL to the public, including Plaintiff, and
 as such, was unreasonably subjected to the risk of injury or death from the
 implantation of BIOCELL Textured Breast Implants.

371. Despite such knowledge, Defendants, and each of them, acting through 6 their officers, directors and managing agents for the purpose of enhancing 7 Defendants' profits, knowingly and deliberately failed to remedy the known defects 8 in said BIOCELL Textured Breast Implants and failed to warn the public, including 9 Plaintiff, of the risk of developing BIA-ALCL occasioned by said defects inherent 10 in said BIOCELL Textured Breast Implants. Said Defendants and their individual 11 agents, officers, and directors intentionally proceeded with the manufacturing, sale, 12 distribution, and marketing of said BIOCELL Textured Breast Implants knowing 13 persons would be exposed to serious danger in order to advance Defendants' own 14 pecuniary interests and monetary profits. 15

372. Defendants conduct was despicable, and so-contemptible that it would
be looked down upon and despised by ordinary decent people, and was carried on
by Defendants with willful and conscious disregard for the safety of Plaintiff,
entitling Plaintiff to exemplary damages.

PRAYER FOR RELIEF

THEREFORE, Plaintiff demands judgment for the following:

20

21

22

23

24

25

26

27

28

- 1. Past and future medical and incidental expenses, according to proof;
- 2. Past and future loss of earnings and/or earning capacity, according to proof;
 - 3. Past and future general damages, according to proof;

4. Punitive and exemplary damages in an amount to be determined at trial;

1	5. Prej	udgment and post	judgment interest;
2	6. Costs to bring this action; and		
3	7. Sucl	h other and further	relief as the court may deem just and proper.
4			
5		<u>JU</u>	RY DEMAND
6	Plaintiff de	emands a trial by ju	ary on all issues so triable.
7			
8			
9	Dated: April 27,	2020 Res	spectfully submitted,
10			
11		By:	
12			BENTLEY & MORE LLP GREGORY L. BENTLEY # 151147
13			Email: gbentley@bentleymore.com
14			KEITH P. MORE # 140679
15			Email: <i>kmore@bentleymore.com</i> CLARE H. LUCICH # 287157
16			Email: clucich@betnleymore.com
17			4931 Birch Street Newport Beach, CA 92660
18			Phone: (949) 870-3800
19			Facsimile: (949) 732-6291
20			PANISH SHEA & BOYLE LLP
21			BRIAN J. PANISH # 116060
22			panish@psblaw.com KEVIN R. BOYLE # 192718
23			boyle@psblaw.com
24			PETER L. KAUFMAN # 269297 kaufman@psblaw.com
25			11111 Santa Monica Boulevard, Suite 700
26			Los Angeles, California 90025
27			Telephone: (310) 477.1700 Facsimile: (310) 477.1699
28			
			-100-
COMPLAINT AND DI		COMPLAINT A	ND DEMAND FOR JURY TRIAL